| |
-A1-Antitrypsin
-A1AN P-type
-A1AN Pi
-A1AT
-A1CE
-AAT
-ABG
-ABO and Rh (D) Type (ABRH)
-ABO and Rh (D) Type, Directed Donor (TBLD)
-Abscess Culture
-Abscess Culture Actinomycosis
-Absolute Eosinophil Count
-ACA
-ACAB
-ACE
-Acetaminophen, Serum (ACT)
-Acetoacetic Acid, Semiquantitative
-Acetone, Semiquantitative (SACE)
-Acetylcholine Receptor Blocking Autoantibody (ACRBA)
-Acetylcholine Receptor Modulating Autoantibody (ACRAM)
-Acetylcholine Receptor Antibody
-Acetylcholine Receptor Binding Autoantibody (ACRA)
-Acetylcholinesterase, Erythrocytes
-Acetylsalicylic Acid
-ACHRA
-Acid Elution for Fetal Hemoglobin
-Acid Fast Bacilli, DNA Probe (AFBP)
-Acid Phosphatase, Prostatic (PACP)
-Acid-Fast Bacteria
-Acid-Fast Culture
-Acid-Fast Stain (AFSM)
-ACL
-ACMA
-ACTH
-Actinomyces Culture, Anaerobic
-Activated Partial ThromboplastinTime
-Activated Protein C Resistance (APCR)
-Acute Hepatitis Panel
-Acylcarnitines, Quantitative (ACYLC)
-Adapin®
-Adenovirus Antibody Profile (ADVAB)
-Adenovirus Culture
-ADH
-Adrenal Antibody
-Adrenal Autoantibody (ADRAB)
-Adrenocorticotropic Hormone (ACTH)
-Aerobic Culture, Tissue
-AFB Culture
-AFB Probe
-AFB Smear
|
|
|
|
Print |
| A1AN Pi |
| |
| See Alpha1-Antitrypsin, Phenotype |
Print |
| A1AN P-type |
| |
| See Alpha1-Antitrypsin, Phenotype |
Print |
| A1-Antitrypsin |
| |
| See Alpha1-Antitrypsin, Quantitative |
Print |
| A1CE |
| |
| See Angiotensin-1-Converting Enzyme, Cerebrospinal Fluid |
| See Angiotensin-1-Converting Enzyme, Serum |
Print |
| A1AT |
| |
| See Alpha1-Antitrypsin, Quantitative |
Print |
| AAT |
| |
| See Alpha1-Antitrypsin, Quantitative |
Print |
| ABG |
| |
| See Blood Gas, Arterial |
| See ABO and Rh (D) Type, Directed Donor |
Print |
| ABO and Rh (D) Type |
| |
| Includes: |
• ABO • Rh (D) NOTE: This test is performed on all specimens submitted for Type and Antibody Screen and Type and Crossmatch tests. |
| |
| CPT: |
86900, 86901 |
| |
| Alternate Name: |
• ABO and Rh (D) Type • Blood Grouping and Rh Typing • Blood Type • Group and Type • Rh Type • Type and Rh |
| |
| Methodology: |
Hemagglutination |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1-3 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
3 mL whole blood |
| |
| Container: |
Lavender top (EDTA) tube |
| |
| Special Instructions and/or Comments: |
| Non-hospitalized patients: Submit specimen with a completed Blood Bank Requisition (LAB-04) Form. |
| |
| Reference Range: |
• A positive OR A negative • O positive OR O negative • B positive OR B negative • AB positive OR AB negative |
| |
Print |
| ABO and Rh (D) Type, Directed Donor |
| |
| Includes: |
• ABO • Rh (D) |
| |
| CPT: |
86900, 86901 |
| |
| Alternate Name: |
ABO and Rh Type; Blood Type |
| |
| Methodology: |
Hemagglutination |
| |
| Testing Schedule: |
Routine, daily |
| |
| Report Available: |
1-3 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
3 mL whole blood |
| |
| Container: |
Lavender top (EDTA) tube |
| |
| Special Instructions and/or Comments: |
| Non-hospitalized patients: Submit specimen with a completed Blood Bank Requisition (LAB-04) Form. |
| |
Print |
| Abscess Culture |
| |
| See Culture, Wound, Aerobic |
Print |
| Abscess Culture Actinomycosis |
| |
| See Culture, Actinomyces, Anaerobic |
Print |
| Absolute Eosinophil Count |
| |
| See Eosinophil Count, Whole Blood |
Print |
| ACA |
| |
| See Cardiolipin Autoantibody Profile |
Print |
| ACAB |
| |
| See Cardiolipin Autoantibody Profile |
Print |
| ACE |
| |
| See Angiotensin-1-Converting Enzyme, Cerebrospinal Fluid |
| See Angiotensin-1-Converting Enzyme, Serum |
Print |
| Acetaminophen, Serum |
| |
| CPT: |
82003 |
| |
| Alternate Name: |
Tylenol® |
| |
| Methodology: |
Endpoint |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum or plasma |
| |
| Container: |
SST tube or red top or EDTA, or heparin plasma |
| |
| Collection: |
The best indicator of acetaminophen toxicity is to measure the drug half-life by analyzing a blood level taken 4 hours post-ingestion, then a second level 3-4 hours later. Half-lives exceeding 4 hours are consistent with hepatic necrosis. |
| |
| Reference Range: |
Therapeutic: 10-20 µg/mL Toxicity Post-Ingestion: • >200 µg/mL within 4 hours of ingestion • >100 µg/mL within 8 hours of ingestion • >50 µg/mL within 12 hours of ingestion |
| |
| Critical Values: |
| >150 µg/mL |
| |
| Clinical Utility: |
| Measurement of acetaminophen in serum or plasma is useful for monitoring toxicity in suspected overdose cases. |
| |
Print |
| Acetoacetic Acid, Semiquantitative |
| |
| See Acetone, Semiquantitative |
Print |
| Acetone, Semiquantitative |
| |
| Includes: |
Detection of acetone and acetoacetic acid only |
| |
| CPT: |
82009 |
| |
| Alternate Name: |
• Acetoacetic Acid, Semiquantitative; Blood • Acetone; Ketone Bodies; Ketones, • Semiquantitative; Nitroprusside Reaction |
| |
| Methodology: |
Nitoprusside Reaction |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum or 1mL plasma or 1 mL urine |
| |
| Container: |
Gold top (serum separator) tube or green top (lithium heparin) OR plastic urine container |
| |
| Special Instructions and/or Comments: |
| Transport to the laboratory immediately. |
| |
| Reference Range: |
| Negative in normal nutritional states. |
| |
| Clinical Utility: |
| Used in the evaluation of alcoholic ketoacidosis, starvation and uncontrolled blood glucose in diabetics. |
| |
Print |
| Acetylcholine Receptor Antibody |
| |
| See Acetylcholine Receptor Binding Autoantibody |
| See Acetylcholine Receptor Blocking Autoantibody |
| See Acetylcholine Receptor Modulating Autoantibody |
Print |
| Acetylcholine Receptor Binding Autoantibody |
| |
| CPT: |
83519 |
| |
| Alternate Name: |
Acetylcholine Receptor • Antibody • ACHRA |
| |
| Methodology: |
Radioimmunoassay (RIA) |
| |
| Testing Schedule: |
Routine, 2 times per week |
| |
| Report Available: |
3-5 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
2 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Special Instructions and/or Comments: |
| Refrigerate |
| |
| Reference Range: |
| < 0.25 nmol/L |
| |
| Clinical Utility: |
| Useful for; Myasthenia gravis (MG) is the most Common neuromuscular transmission disorder. It is an antibody mediated autoimmune disease that stems from a loss of acetylcholine receptors (AChR) at neuromuscular junctions. AChR autoantibodies are diagnostic of MG, and are found in 80-90% of MG patients. AChR binding autoantibodies are present most frequently in MG and provide the most reliable information for diagnostic screening. |
| |
Print |
| Acetylcholine Receptor Blocking Autoantibody |
| |
| CPT: |
83519 |
| |
| Alternate Name: |
• Acetylcholine Receptor Antibody • ACHRA |
| |
| Methodology: |
Radioimmunoassay (RIA) |
| |
| Testing Schedule: |
Routine, 1 time per week |
| |
| Report Available: |
3-5 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Special Instructions and/or Comments: |
| Refrigerate |
| |
| Reference Range: |
| <15% |
| |
Print |
| Acetylcholine Receptor Modulating Autoantibody |
| |
| CPT: |
83519 |
| |
| Alternate Name: |
• Acetylcholine Receptor • Antibody • ACHRA |
| |
| Methodology: |
Radioimmunoassay (RIA) |
| |
| Testing Schedule: |
Routine, 1 time per week |
| |
| Report Available: |
3-5 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
2 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Special Instructions and/or Comments: |
| Refrigerate |
| |
| Reference Range: |
| <20% |
| |
| Clinical Utility: |
| Myasthenia gravis (MG) is the most common neuromuscular transmission disorder. It is an antibody mediated autoimmune disease that stems from a loss of acetylcholine receptors (AChR) at neuromuscular junctions. ACh Rautoantibodies are diagnostic of MG, and are found in 80-90% of MG patients. A small portion of patients with early onset of ocular restricted MG may only have AChR modulation autoantibodies, thus if AChR binding autoantibodies are absent in a patient with weakness or ocular symptoms consistent with MG, AChR modulationg autoantibodies should be ordered. |
| |
Print |
| Acetylcholinesterase, Erythrocytes |
| |
| See Cholinesterase, RBC |
Print |
| Acetylsalicylic Acid |
| |
| See Salicylate, Serum |
Print |
| ACHRA |
| |
| See Acetylcholine Receptor Binding Autoantibody |
| See Acetylcholine Receptor Blocking Autoantibody |
| See Acetylcholine Receptor Modulating Autoantibody |
Print |
| Acid Elution for Fetal Hemoglobin |
| |
| See Kleihauer-Betke Test |
Print |
| Acid Fast Bacilli, DNA Probe |
| |
| CPT: |
87149 |
| |
| Alternate Name: |
• AFB Probe • DNA Probe for Mycobacterium avium-complex • DNA Probe for Mycobacterium gordonae • DNA Probe for Mycobacterium tuberculosis-complex • Mycobacterium gordonae • Mycobacterium Identification by DNA Probe |
| |
| Methodology: |
GEN-PROBE® |
| |
| Testing Schedule: |
1 time per week |
| |
| Report Available: |
1-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
Submit organism in pure culture on a suitable mycobacterial medium. |
| |
| Container: |
Transport viable culture in double sealed metal canister with a biohazard label on the outside of the container. |
| |
| Special Instructions and/or Comments: |
• Specify which DNA probe is to be performed. • Organism may be kept at room temperature. |
| |
| Clinical Utility: |
| This test is used for identification of Mycobacterium tuberculosis complex, Mycobacterium avium complex, and Mycobacterium gordonae by DNA probe from a mycobacterium isolate to determine treatment. |
| |
Print |
| Acid-Fast Bacteria |
| |
| See Culture, Mycobacteria |
| See Acid Fast Stain |
Print |
| Acid-Fast Culture |
| |
| See Culture, Mycobacteria |
Print |
| Acid-Fast Stain |
| |
| CPT: |
87206 |
| |
| Alternate Name: |
• AFB Smear • AFB Stain • Auramine Rhodamine Stain • Fluorochrome Stain • Mycobacterium Stain; TB Stain |
| |
| Methodology: |
Acid fast stain |
| |
| Testing Schedule: |
Routine, daily 0800-1530 |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
•Sputum - these specimens should be a series of 3 consecutive specimens collected in 8-24 hour intervals (24 hours when possible). Early morning sputum specimens are preferred. Sputum specimens are not pooled. A volume of at least 3 ml should be submitted for each sample, but 5 to 10 ml is optimal. There is no advantage in collecting a larger volume. If the specimen submitted is less than 3ml but greater than 1 ml, it is accepted, but a comment is put in under special request to indicate that < 3 ml was submitted and this may compromise results. If less than 1 ml is submitted, the specimen is rejected as “Quantity insufficient”. •Bronchial washing – 1 ml •Cerebrospinal fluid – 5 ml •Urine – 50 ml •Tissue – small piece in sterile container with just enough non-bacteriostatic saline to cover the tissue •Wound – 1 CultureSwab set (if bacterial culture is also required, submit an additional CultureSwab set) |
| |
| Container: |
•Sterile container - for sputum, bronchial washing, cerebrospinal fluid, urine, tissue •CultureSwab set - for wound |
| |
| Collection: |
First morning specimen is preferred for sputum and urine. |
| |
| Special Instructions and/or Comments: |
• Indicate specific site of specimen, current antibiotic therapy, age and sex of patient, collection time and date, and clinical diagnosis on Requisition Form. • Refrigerate. • Cover tissue with sterile broth or saline. |
| |
| Reference Range: |
No acid-fast bacilli seen. NOTE: Positive smears will be quantitated and reported as occasional (3-9 bacilli in entire smear), few (10-100 per smear), or many (>100 per smear). |
| |
| Critical Values: |
| Any positive. |
| |
| Clinical Utility: |
| Acid Fast smears are useful for determining the presence of Mycobacteria in patient specimen. This test does not include a culture and is usually used to monitor the therapy of known positive patients. For diagnosis, both acid-fast stain AND culture should be requested. |
| |
Print |
| Acid Phosphatase, Prostatic |
| |
| CPT: |
84066 |
| |
| Alternate Name: |
PACP • PAP; Prostatic Acid Phosphatase |
| |
| Methodology: |
ICMA |
| |
| Testing Schedule: |
Routine, daily |
| |
| Report Available: |
3-5 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL frozen serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Special Instructions and/or Comments: |
• Transport to the laboratory immediately. • Must be processed and frozen within 4 hours of collection. • Centrifuge tube, transfer to plastic vial and freeze. Once frozen, transport specimen submerged in dry ice. • It is preferred to collect specimen prior to any prostate or rectal examination • This is not the same as an Enzymatic Acid Phosphatase. |
| |
| Reference Range: |
| <3.50 ng/mL |
| |
| Clinical Utility: |
| An adjunct in the evaluation of possible prostatic malignancy and useful in monitoring therapeutic progress. Diagnose carcinoma of prostate, metastatic; monitor therapy with antineoplastic drugs in prostatic cancer; evaluate possible histiocytosis. Moderate elevations of total acid phosphatase can be seen with malignant invasion of bone, myelocytic leukemia, Paget’s disease, hyperparathyroidism with skeletal involvement, Gaucher’s disease, and Neimann-Pick disease. Spurious elevations may occur in hemolytic disease and with impaired kidney function |
| |
Print |
| ACL |
| |
| See Cardiolipin Autoantibody Profile |
Print |
| ACMA |
| |
| See Centromere Autoantibody |
Print |
| ACTH |
| |
| See Adrenocorticotropic Hormone |
Print |
| Actinomyces Culture, Anaerobic |
| |
| See Culture, Actinomyces, Anaerobic |
Print |
| Activated Partial ThromboplastinTime |
| |
| See Partial Thromboplastin Time, Activated, Plasma |
Print |
| Activated Protein C Resistance |
| |
| CPT: |
85307 |
| |
| Alternate Name: |
• APC-R • APC Resistance • Resistance to Activated Protein C |
| |
| Methodology: |
Clot Based Assay |
| |
| Testing Schedule: |
Routine, 1 time per week |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
2 mL prepared “platelet poor plasma”, split evenly into 2 plastic aliquot tubes and FROZEN immediately. |
| |
| Container: |
2 Blue top (sodium citrate) tubes |
| |
| Collection: |
See special handling instructions for “Coagulation Studies”, listed under Specimen Collection, Preparation, and Handling. |
| |
| Special Instructions and/or Comments: |
Testing is contraindicated for patients on Heparin or Coumadin therapy. Preparation and submission of “platelet poor plasma” is critical for accurate test performance and interpretation. See collection note above. Causes for rejection: • Extended transport time to laboratory • Clotted specimens • Hemolyzed specimens • Blue top sodium citrate tubes insufficiently filled • Aliquots not received frozen on dry ice • Frozen aliquots not clearly identified as “platelet poor plasma”. |
| |
| Reference Range: |
Negative.....................Ratio >2.0 No APC resistant Factor V identified) |
| |
| Clinical Utility: |
| Useful for Screening test for Factor V Leiden, with sensitivity approaching 100%. APCR is the most commonly recognized abnormality among patients with venous thromboembolism. |
| |
Print |
| Acute Hepatitis Panel |
| |
| See Hepatitis Panel, Acute |
Print |
| Acylcarnitines, Quantitative |
| |
| CPT: |
82017 |
| |
| Methodology: |
Electrospray Tandem Mass Spectrometry (MS/MS) |
| |
| Testing Schedule: |
Routine, daily |
| |
| Report Available: |
7-10 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1.0 Na Heparin plasma |
| |
| Collection: |
Collect just prior to a meal or scheduled feeding |
| |
| Special Instructions and/or Comments: |
| Centrifuge, transfer plasma to plastic aliquot tube and freeze. Once frozen, transport specimen submerged in dry ice |
| |
| Reference Range: |
| Age specific reference ranges accompany the report |
| |
| Clinical Utility: |
| Useful for diagnosis of fatty acid beta-oxidation disorders and several organic aciduric. For most inborn errors of metabolism involving fatty acid beta oxidation, this is the most informative screening test. Quantitative acylcarnitine analysis can also be used to evaluate the treatment during follow up of patients with these disorders. |
| |
Print |
| Adapin® |
| |
| See Doxepin |
Print |
| Adenovirus Antibody Profile |
| |
| Includes: |
Total Anitibody |
| |
| CPT: |
86603 |
| |
| Methodology: |
Complement Fixation |
| |
| Testing Schedule: |
Routine, daily |
| |
| Report Available: |
3-5 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Special Instructions and/or Comments: |
| Refrigerate |
| |
| Reference Range: |
| <1:8 |
| |
| Clinical Utility: |
Useful for diagnosis of the diagnosis of Adenovirus Infections. Single titers > 1:64 are indicative of recent or current infection. Titers of 1:8 - 1:32 may be indicative of either past or recent infection, since CF antibody levels persist for only a few months. A four-fold or greater increase in titer between acute and convalescent specimens confirms the diagnosis. |
| |
Print |
| Adenovirus Culture |
| |
| See Culture, Viral, Respiratory |
Print |
| ADH |
| |
| See Antidiuretic Hormone |
Print |
| Adrenal Antibody |
| |
| See Adrenal Autoantibody |
Print |
| Adrenal Autoantibody |
| |
| CPT: |
83519 |
| |
| Alternate Name: |
• Adrenal Antibody • Anti-Adrenal Antibody • 21-Hydroxylase Antibody |
| |
| Methodology: |
Immunoabsorption Assay |
| |
| Testing Schedule: |
Routine, 1 time per week |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Special Instructions and/or Comments: |
| • Centrifuge, transfer to plastic aliquot tube and freeze. • Once frozen, transport specimen submerged in dry ice. |
| |
| Reference Range: |
| < 1 U/mL |
| |
Print |
| Adrenocorticotropic Hormone |
| |
| CPT: |
82024 |
| |
| Alternate Name: |
ACTH |
| |
| Methodology: |
Automated Chemiluminescent Immunometric Assay |
| |
| Testing Schedule: |
Routine, 2 times per week |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL plasma |
| |
| Container: |
Prechilled lavender top (EDTA) tube |
| |
| Collection: |
Morning (6am-10am) specimens are desirable. |
| |
| Special Instructions and/or Comments: |
• Transport to the laboratory immediately. • Must be processed and frozen immediately. • Centrifuge, transfer to plastic aliquot tube and freeze. • Once frozen, transport specimen submerged in dry ice. |
| |
| Reference Range: |
| Adults: 10-60 pg/mL (am draws) |
| |
| Clinical Utility: |
| Useful for determining the cause of Hypercortisolism and hypocortislolism states. |
| |
Print |
| Aerobic Culture, Tissue |
| |
| See Culture, Tissue, Aerobic |
Print |
| AFB Culture |
| |
| See Culture, Mycobacteria |
Print |
| AFB Probe |
| |
| See Acid Fast Bacilli by DNA Probe |
Print |
| AFB Stain |
| |
| See Acid-Fast Stain |
Print |
| AFB Smear |
| |
| See Acid-Fast Stain |
Print |
| AFFIRM VPIII® |
| |
| See Vaginitis DNA Probe |
Print |
| AFP |
| |
| See Alpha-Fetoprotein, Tumor Marker |
Print |
| AFP-3 |
| |
| See Triple Screen, Maternal Serum |
Print |
| AFP-4 |
| |
| See Quad Screen, Maternal Serum |
Print |
| AFP, Maternal Serum |
| |
| See Alpha-Fetoprotein, Maternal Serum |
Print |
| Aggregometer Test |
| |
| See Platelet Aggregation |
Print |
| AHF |
| |
| See Factor Activity Assays |
Print |
| ALA, Urine |
| |
| See Aminolevulinic Acid (ALA) Urine, 24-HR |
Print |
| Alanine Aminotransferase, Serum |
| |
| CPT: |
84460 |
| |
| Alternate Name: |
• Alanine Transferase • ALT; GPT • Serum Glutamic Pyruvate Transaminase • SGPT |
| |
| Methodology: |
HNL: Rate LPP: Bichromatic Rate |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Reference Range: |
HNL • 7-40 units/L LPP • Male:..............................21-72 units/L • Female:............................9-52 units/L |
| |
| Clinical Utility: |
| Useful for the evaluation of hepatic function and hepatic disorders. |
| |
Print |
| Alanine Transferase |
| |
| See Alanine Aminotransferase, Serum |
Print |
| Albumin, Body Fluid |
| |
| CPT: |
82042 |
| |
| Alternate Name: |
Body Fluid Albumin |
| |
| Methodology: |
Endpoint |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL body fluid |
| |
| Container: |
Red top tube, no serum separator |
| |
| Reference Range: |
| Not established, must be interpreted with clinical findings. |
| |
Print |
| Albumin, Serum |
| |
| CPT: |
82040 |
| |
| Methodology: |
HNL: Endpoint LPP : Polychromatic endpoint |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Reference Range: |
• < 2 days: ........................2.4-4.8 g/dL • > 2 days: ........................3.0-5.1 g/dL • > 7 days: ........................3.5-4.7 g/dL • > 3 years:........................3.5-5.0 g/dL |
| |
| Clinical Utility: |
Useful for evaluating hepatic disorders, nephrotic syndrome and evaluation of nutritional status. |
| |
Print |
| Alcohol, Serum or Plasma |
| |
| CPT: |
82055 |
| |
| Alternate Name: |
• Ethanol • Ethyl Alcohol • ETOH |
| |
| Methodology: |
Enzymatic |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum OR plasma |
| |
| Container: |
Red top or SST tube, OR gray top (sodium fluoride) tube |
| |
| Special Instructions and/or Comments: |
| Centrifuge, but DO NOT uncap tube. |
| |
| Reference Range: |
• Negative • Intoxication:................ 50-100 mg/dL • Comatose:.................... 300-500 mg/dL • Fatal............................. > 400 mg/dL |
| |
| Clinical Utility: |
Useful for the detection and quantitation of ethanol in serum or plasma to document recent use or administration of ethanol and assess the degree of intoxication. Note: Ethanol may be formed in biological specimens in vitro by microorganisms if a proper preservative such as sodium fluoride is not used. |
| |
Print |
| Alcohol, Urine with Confirmation |
| |
| Includes: |
• Quantitation of ethanol in urine. • Positive result reflexed to confirmation by Gas Chromatography |
| |
| CPT: |
80101 |
| |
| Alternate Name: |
Urine Ethanol |
| |
| Methodology: |
Enzymatic |
| |
| Testing Schedule: |
Routine, daily |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
5 mL fresh random urine |
| |
| Container: |
Plastic urine container OR gray top (sodium fluoride) tube for medicolegal specimens |
| |
| Collection: |
Freshly voided random urine. |
| |
| Reference Range: |
| Negative |
| |
| Clinical Utility: |
To detect ethanol consumption or use up to 12 hours prior to sample collection. NOTE: Ethanol may be formed in biological specimens in vitro by microorganisms if a proper preservative such as sodium fluoride is not used. |
| |
Print |
| Alcohol, Urine with Confirmation, Forensic |
| |
| Includes: |
• Quantititation of ethanol in urine • Positive result reflexed to confirmation by Gas Chromatrography (GC) |
| |
| CPT: |
80101 |
| |
| Alternate Name: |
Urine Ethanol |
| |
| Methodology: |
Enzymatic |
| |
| Testing Schedule: |
Routine, Monday-Friday only |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
5 mL fresh random urine |
| |
| Container: |
Plastic urine container OR gray top (sodium fluoride) tube for medicolegal specimens |
| |
| Collection: |
Freshly voided randomurine. |
| |
| Reference Range: |
| Negative |
| |
| Clinical Utility: |
Useful for the detection of ethanol consumption or use up to 12 hours prior to sample collection. Note: Ethanol may be formed in biological specimens in vitro by microorganisms if a proper preservative such as sodium fluoride is not used. |
| |
Print |
| Alcohol, Urine without Confirmation |
| |
| Includes: |
Qualitative result of ethanol in urine. |
| |
| CPT: |
80101 |
| |
| Alternate Name: |
Urine Ethanol |
| |
| Methodology: |
Enzymatic |
| |
| Testing Schedule: |
Routine, daily |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
5 mL fresh random urine |
| |
| Container: |
Plastic urine container OR gray top (sodium fluoride) tube for medicolegal specimens |
| |
| Collection: |
Freshly voided random urine. |
| |
| Reference Range: |
| Negative |
| |
| Clinical Utility: |
Useful for the detection of ethanol consumption or use up to 12 hours prior to sample collection. Note:Ethanol may be formed in biological specimens in vitro by microorganisms if a proper preservative such as sodium fluoride is not used. |
| |
Print |
| Alcohol, Whole Blood |
| |
| Includes: |
Identification and quantitation of ethanol. |
| |
| CPT: |
82055 |
| |
| Alternate Name: |
• Ethanol Level • Whole Blood Alcohol |
| |
| Methodology: |
Gas Chromatography (GC) |
| |
| Testing Schedule: |
Routine, 3 times per week |
| |
| Report Available: |
1-3 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
2 mL whole blood |
| |
| Container: |
Gray top (sodium fluoride) tube |
| |
| Collection: |
• Prepare venipuncture site using iodine, not alcohol. • Place evidence seal over cap of tube. |
| |
| Special Instructions and/or Comments: |
| Submit specimen with a completed Blood Alcohol Toxicology Request/Chain of Custody (LAB-32) Form or Drug Testing Request and Chain of Custody (HNL-53) Form in evidence bag if for medical-legal purposes. |
| |
| Reference Range: |
• Negative • Legally intoxicated (PA):............0.08% • Toxic:..........................................> 0.25% |
| |
| Clinical Utility: |
Useful in the detection and quantitation of ethanol in whole blood to document recent use or administration of ethanol and assess the degree of intoxication. NOTE: Ethanol may be formed in biological specimens in vitro by microorganisms if a proper preservative such as sodium fluoride is not used. |
| |
Print |
| Alcohol, Whole Blood, Legal |
| |
| Includes: |
• Identification and quantitation of ethanol by Gas Chromatography. • Reflex confirmation of positives by an enzymatic procedure. Used for legal and forensic testing. |
| |
| CPT: |
82055 |
| |
| Alternate Name: |
Legal Alcohol |
| |
| Methodology: |
Gas Chromatography (GC); Enzymatic |
| |
| Testing Schedule: |
Routine, 3 times per week |
| |
| Report Available: |
1-3 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
2 mL whole blood |
| |
| Container: |
Gray top (sodium fluoride) tube |
| |
| Collection: |
Prepare venipuncture site using iodine, not alcohol. Place evidence seal over cap of tube. |
| |
| Special Instructions and/or Comments: |
| Submit specimen with a completed Blood Alcohol Toxicology Request/Chain of Custody (LAB-32) Form or Drug Testing Request and Chain of Custody (HNL-53) Form in evidence bag. |
| |
| Reference Range: |
• Negative • Legally intoxicated (PA):...............0.08% • Toxic:........................................... > 0.25% |
| |
| Clinical Utility: |
Useful in the detection and quantitation of ethanol in whole blood to document recent use or administration of ethanol and assess the degree of intoxication. Note: Ethanol may be formed in biological specimens in vitro by microorganisms if a proper preservative such as sodium fluoride is not used. |
| |
Print |
| Aldolase |
| |
| CPT: |
82085 |
| |
| Methodology: |
Ultraviolet (UV), Kinetic |
| |
| Testing Schedule: |
Routine, daily |
| |
| Report Available: |
2-4 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Red top (NO serum separator) tube |
| |
| Collection: |
Fasting patient preferred |
| |
| Special Instructions and/or Comments: |
• Centrifuge, transfer to plastic aliquot tube and freeze. • Once frozen, transport specimen submerged in dry ice. • Hemolyzed specimens are NOT acceptable. |
| |
| Reference Range: |
0-16 years:......................<14.5 U/L >17 years:.......................<7.7 U/L |
| |
| Clinical Utility: |
| Useful in the detection of muscle disease. |
| |
Print |
| Aldosterone, Serum |
| |
| CPT: |
82088 |
| |
| Methodology: |
Liquid Chromatography- Tandem Mass Spectrometry (LC-MS/MS) |
| |
| Testing Schedule: |
Routine, 5 times per week |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
2.5 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Collection: |
Collect at 8am |
| |
| Special Instructions and/or Comments: |
• Transport to the laboratory immediately. • Centrifuge, transfer to plastic aliquot tube and freeze. • Once frozen, transport specimen submerged in dry ice. |
| |
| Reference Range: |
0-30.................................17-154.0 ng/dL 1-11 months...................6.5-86.0 ng/dL 1-10 years.......................< 40 ng/dL (supine) ............................................< 124 ng/dL (upright) > 11 years........................21 ng/dLam periphereal vein specimen Reference Range based on upright am collection from subjects on ad lib sodium untake. |
| |
| Clinical Utility: |
| Useful for investigating primary aldosteronism (e.g., adrenal andenoma/carcinoma and adrenal Cortical hyperplasia) and secondary aldosteronism (renovascular disease, salt depletion, potasium loading, cardiac failure with ascites, pregnancy, Bartter’s syndrome). |
| |
Print |
| Aldosterone, 24-Hour Urine |
| |
| Includes: |
• Volume Measurement • Collection Period • Aldosterone, Urine |
| |
| CPT: |
81050, 82088 |
| |
| Methodology: |
Liquid Chromatography- Tandem Mass Spectrometry (LC-MS/MS) |
| |
| Testing Schedule: |
Routine, 3 times per week |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
25 mL of a 24-Hour urine collection |
| |
| Container: |
• 24-Hour plastic urine container • Add 25 mL of 50% acetic acid at start of collection period. |
| |
| Collection: |
• Instruct the patient to void at the beginning of the collection period and discard the specimen. • Collect all urine including the final specimen voided at the end of collection period. • Refrigerate during collection. • Container must be labeled with the patient’s name. |
| |
| Special Instructions and/or Comments: |
• Instruct patient not to void directly into container. • Transport to the laboratory promptly. |
| |
| Reference Range: |
0-30 days...........................0.7-11.0 ug/24 hours* 1-11 months:......................0.7-22.0 ug/24 hours* > 1 year:.............................2.0-20.0 ug/24 hours* * Loeuille GA, Racadot A, Vasseur P, Vandewalle B: Blood and urinary aldosterone levels in normal neonates, infants and children. Pediatrie 1981;36:335-344 |
| |
| Clinical Utility: |
Useful for investigation of primary aldosteronism (e.g., adrenal andenoma/carcinoma and adrenal Cortical hyperplasia) and secondary aldosteronism (renovascular disease, salt depletion, potassium loading, cardiac failure with ascites, pregnancy, Bartter’s syndrome). |
| |
Print |
| Alk Phos |
| |
| See Alkaline Phosphatase, Total, Serum |
Print |
| Alkaline Hemoglobin Electrophoresis |
| |
| See Hemoglobin Electrophoresis |
Print |
| Alkaline Phosphatase, Bone Specific |
| |
| CPT: |
84080 |
| |
| Alternate Name: |
Bone Alkaline Phosphatase |
| |
| Methodology: |
Immunoenzymatic Assay |
| |
| Testing Schedule: |
Routine, 5 times per week |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Special Instructions and/or Comments: |
| Refrigerate |
| |
| Reference Range: |
• Males:.......................................... < 20 ug/L • Females: Premenopausal...................... < 14 ug/L Post menopausal................... < 22 µg/L |
| |
| Clinical Utility: |
| Useful in the diagnosis and assessment of severity of metabolic bone disease including Paget’s disease, osteromalacia, and other states of high bone turnover. It also could be used to monitor the efficacy of antiresorptive therapies including post-menopausal osteroporosis treatment. This assay is not intended as a screening for osteroporosis. Diagnosis of osteoporosis should be made on the basis of bone density. |
| |
Print |
| Alkaline Phosphatase, Isoenzymes |
| |
| Includes: |
• Alkaline Phosphatase • Total Alkaline Phosphatase • Isoenzymes: Liver, Bone, Intestine |
| |
| CPT: |
84075, 84080 |
| |
| Alternate Name: |
ALP Isoenzymes |
| |
| Methodology: |
Agarose Electrophoresis, Kinetic Spectrophotometry |
| |
| Testing Schedule: |
Routine, 5 times per week |
| |
| Report Available: |
3-5 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
2 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Special Instructions and/or Comments: |
| • Centrifuge, transfer to plastic aliquot tube and freeze. • Once frozen, transport specimen submerged in dry ice. |
| |
| Reference Range: |
| Accompanies Report |
| |
| Clinical Utility: |
| Useful for determining the tissue source of increased (ALP) activity in serum. It can also be used to differentiate between a liver and bone source of ALP. |
| |
Print |
| Alkaline Phosphatase, Total, Serum |
| |
| CPT: |
84075 |
| |
| Alternate Name: |
ALKP • Alk Phos • ALP • Phosphatase, Alkaline |
| |
| Methodology: |
HNL: Rate LPP: Bichromatic Rate |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Reference Range: |
• <1 month:.................30-250 units/L • >1 month:.................30-175 units/L • >2 years:...................30-200 units/L • >7 years: ..................30-250 units/L • >15 years: ................30-136 units/L |
| |
| Clinical Utility: |
| Useful in the evaluation of hepatic function and hepatic or bone disorders. |
| |
Print |
| ALKP |
| |
| See Alkaline Phosphatase, Total, Serum |
Print |
| Allergen Profile, Asthma |
| |
| Includes: |
Includes a Total IgE along with the following specific IgE allergens: • Molds: Alternaria alternata, Aspergillus fumigatus, Candida albicans, Cladosporium herbarium, Mucor racemosus • Miscellaneous: Cat dander, Dog dander, Cockroach, Common ragweed, Timothy grass, Oak, House dust mites: D. farinae and D. pteronyssius |
| |
| CPT: |
82785, 86003 (x13) |
| |
| Alternate Name: |
Asthma Allergen Profile |
| |
| Methodology: |
ImmunoCAP (FEIA) |
| |
| Testing Schedule: |
Routine, 4-6 times per week |
| |
| Report Available: |
3-5 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
4 mL serum |
| |
| Container: |
2 Gold top (serum separator) tubes |
| |
| Special Instructions and/or Comments: |
| Refrigerate |
| |
| Reference Range: |
• Total IgE: See individual test listing • Specific IgE Allergens: See chart below | Class | IgE ku/L | Interpretation | | 0 | <0.10 | Negative | | 0/1 | 0.10-0.35 | Borderline | | 1 | 0.35-0.69 | Equivocal | | 2 | 0.70-3.4 | Positive | | 3 | 3.5-17.4 | Positive | | 4 | 17.5-49.9 | Strongly Positive | | 5 | 50.0-100.0 | Strongly Positive | | 6 | >100.0 | Strongly Positive |
|
| |
| Clinical Utility: |
| Useful forAllergen specific IgE levels (kU/L) provide 95% Positive Predictive Values (PPV) for clinical reactivity to the specific allergen challenge. |
| |
Print |
| Allergen Profile, Atopic Dermatitis |
| |
| Includes: |
Includes a Total IgE along with the following specific IgE allergens: • Foods: Egg white, Fish (Cod), Milk, Peanut, Soybean, Wheat • Miscellaneous: Cat dander, Alternaria alternata, House dust mite (D. farinae), Common ragweed, Timothy grass, Oak, Staphylococcal Enterotoxins A and B |
| |
| CPT: |
82785, 86003 (X14) |
| |
| Alternate Name: |
Atopic Dermatitis Allergen Profile |
| |
| Methodology: |
ImmunoCAP (FEIA) |
| |
| Testing Schedule: |
Routine, 4-6 times per week |
| |
| Report Available: |
3-5 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
4 mL serum |
| |
| Container: |
2 Gold top (serum separator) tubes |
| |
| Special Instructions and/or Comments: |
| Refrigerate |
| |
| Reference Range: |
• Total IgE: See individual test listing • Specific IgE Allergens: See chart below | Class | IgE ku/L | Interpretation | | 0 | <0.10 | Negative | | 0/1 | 0.10-0.35 | Borderline | | 1 | 0.35-0.69 | Equivocal | | 2 | 0.70-3.4 | Positive | | 3 | 3.5-17.4 | Positive | | 4 | 17.5-49.9 | Strongly Positive | | 5 | 50.0-100.0 | Strongly Positive | | 6 | >100.0 | Strongly Positive |
|
| |
| Clinical Utility: |
| Useful for Allergen specific IgE levels (kU/L) provide 95% Positive Predictive Values (PPV) for clinical reactivity to the specific allergen challenge. |
| |
Print |
| Allergen Profile, Food, Basic |
| |
| Includes: |
Includes a Total IgE along with the following specific IgE allergens: • Chicken, Clam, Corn (Maize), Egg White, Fish (Cod), Milk, Peanut, Shrimp, Soybean, Tomato, Walnut, Wheat |
| |
| CPT: |
82785, 86003 (x12) |
| |
| Alternate Name: |
Food Allergen Profile, Basic |
| |
| Methodology: |
ImmunoCAP (FEIA) |
| |
| Testing Schedule: |
Routine, 4-6 times per week |
| |
| Report Available: |
3-5 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
4 mL serum |
| |
| Container: |
2 Gold top (serum separator) tubes |
| |
| Special Instructions and/or Comments: |
| Refrigerate |
| |
| Reference Range: |
• Total IgE: See individual test listing • Specific IgE Allergens: See chart below | Class | IgE ku/L | Interpretation | | 0 | <0.10 | Negative | | 0/1 | 0.10-0.35 | Borderline | | 1 | 0.35-0.69 | Equivocal | | 2 | 0.70-3.4 | Positive | | 3 | 3.5-17.4 | Positive | | 4 | 17.5-49.9 | Strongly Positive | | 5 | 50.0-100.0 | Strongly Positive | | 6 | >100.0 | Strongly Positive |
|
| |
| Clinical Utility: |
| Useful for Allergen specific IgE levels (kU/L) provide 95% Positive Predictive Values (PPV) for clinical reactivity to the specific allergen challenge. |
| |
Print |
| Allergen Profile, Food, Nut |
| |
| Includes: |
Includes a Total IgE along with the following specific IgE allergens: • Almond, Brazilnut, Cashew, Hazelnut, Peanut, Pecan, Pistachio, Walnut |
| |
| CPT: |
82785, 86003 (x8) |
| |
| Alternate Name: |
Food Allergen Profile, Nut |
| |
| Methodology: |
ImmunoCAP (FEIA) |
| |
| Testing Schedule: |
Routine, 4-6 times per week |
| |
| Report Available: |
3-5 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
4 mL serum |
| |
| Container: |
2 Gold top (serum separator) tubes |
| |
| Special Instructions and/or Comments: |
| Refrigerate |
| |
| Reference Range: |
• Total IgE: See individual test listing • Specific IgE Allergens: See chart below | Class | IgE ku/L | Interpretation | | 0 | <0.10 | Negative | | 0/1 | 0.10-0.35 | Borderline | | 1 | 0.35-0.69 | Equivocal | | 2 | 0.70-3.4 | Positive | | 3 | 3.5-17.4 | Positive | | 4 | 17.5-49.9 | Strongly Positive | | 5 | 50.0-100.0 | Strongly Positive | | 6 | >100.0 | Strongly Positive |
|
| |
| Clinical Utility: |
| Useful for Allergen specific IgE levels (kU/L) provide 95% Positive Predictive Values (PPV) for clinical reactivity to the specific allergen challenge. |
| |
Print |
| Allergen Profile, Food, Shellfish |
| |
| Includes: |
Includes a Total IgE along with the following specific IgE allergens: • Blue Mussel, Clam, Crab, Fish (Cod), Lobster, Scallop, Shrimp, Tuna |
| |
| CPT: |
82785, 86003 (X8) |
| |
| Alternate Name: |
Food Allergen Profile, Shellfish |
| |
| Methodology: |
ImmunoCAP (FEIA) |
| |
| Testing Schedule: |
Routine, 4-6 times per week |
| |
| Report Available: |
3-5 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
4 mL serum |
| |
| Container: |
2 Gold top (serum separator) tubes |
| |
| Special Instructions and/or Comments: |
| Refrigerate |
| |
| Reference Range: |
• Total IgE: See individual test listing • Specific IgE Allergens: See chart below | Class | IgE ku/L | Interpretation | | 0 | <0.10 | Negative | | 0/1 | 0.10-0.35 | Borderline | | 1 | 0.35-0.69 | Equivocal | | 2 | 0.70-3.4 | Positive | | 3 | 3.5-17.4 | Positive | | 4 | 17.5-49.9 | Strongly Positive | | 5 | 50.0-100.0 | Strongly Positive | | 6 | >100.0 | Strongly Positive |
|
| |
| Clinical Utility: |
| Useful for allergen specific IgE levels (kU/L) provide 95% Positive Predictive Values (PPV) for clinical reactivity to the specific allergen challenge. |
| |
Print |
| Allergen Profile, Northeastern Upper Respiratory Disease |
| |
| Includes: |
Includes a Total IgE along with the following specific IgE allergens: • Tree Pollens: Box Elder/Maple, Elm, Oak, Silver Birch, Walnut • Grass Pollens: Bermuda, Meadow/Kentucky Blue (June), Orchard, Rye, Timothy • Weed Pollens: Commmon ragweed, English plantain, Goosefoot (Lamb’s quarters), Russian thistle (Saltwort) • Molds: Alternaria alternata, Aspergillus fumigatus, Cladosporium herbarium, Helminthosporium halodes, Penicillium notatum • Miscellaneous: House dust mites: D. pteronyssius and D. farinae, House dust/Hollister-Stier Labs, Cat dander, Dog dander, Cockroach |
| |
| CPT: |
82785, 86003 (x25) |
| |
| Alternate Name: |
• NE Allergen Profile • NE Allergy Screen • Northeast Allergen Profile • Northeastern URD Profile |
| |
| Methodology: |
ImmunoCAP (FEIA) |
| |
| Testing Schedule: |
Routine, 4-6 times per week |
| |
| Report Available: |
3-5 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
6 mL serum |
| |
| Container: |
3 Gold top (serum separator) tubes |
| |
| Special Instructions and/or Comments: |
| Refrigerate |
| |
| Reference Range: |
• Total IgE: See individual test listing • Specific IgE Allergens: See chart below | Class | IgE ku/L | Interpretation | | 0 | <0.10 | Negative | | 1 | 0.35-0.69 | Equivocal | | 2 | 0.70-3.4 | Positive | | 3 | 3.5-17.4 | Positive | | 4 | 17.5-49.9 | Strongly Positive | | 5 | 50.0-100.0 | Strongly Positive | | 6 | >100.0 | Strongly Positive |
|
| |
| Clinical Utility: |
| Useful for allergen specific IgE levels (kU/L) provide 95% Positive Predictive Values (PPV) for clinical reactivity to the specific allergen challenge. |
| |
Print |
| Allergen Profile, Otitis Media |
| |
| Includes: |
Includes a Total IgE along with the following specific IgE allergens: • Foods: Chicken, Corn (Maize), Egg White, Fish (Cod), Milk, Peanut, Soybean, Tomato, Wheat • Miscellaneous: Cat dander, Alternaria alternata, House dust mite (D. farinae), Common ragweed, Timothy grass, Oak |
| |
| CPT: |
82785, 86003 (x15) |
| |
| Alternate Name: |
Otitis Media Allergen Profile |
| |
| Methodology: |
ImmunoCAP (FEIA) |
| |
| Testing Schedule: |
Routine, 4-6 times per week |
| |
| Report Available: |
3-5 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
4 mL serum |
| |
| Container: |
2 Gold top (serum separator) tubes |
| |
| Special Instructions and/or Comments: |
| Refrigerate |
| |
| Reference Range: |
• Total IgE: See individual test listing • Specific IgE Allergens: See chart below | Class | IgE ku/L | Interpretation | | 0 | <0.10 | Negative | | 0/1 | 0.10-0.35 | Borderline | | 1 | 0.35-0.69 | Equivocal | | 2 | 0.70-3.4 | Positive | | 3 | 3.5-17.4 | Positive | | 4 | 17.5-49.9 | Strongly Positive | | 5 | 50.0-100.0 | Strongly Positive | | 6 | >100.0 | Strongly Positive |
|
| |
| Clinical Utility: |
| Allergen specific IgE levels (kU/L) provide 95% Positive Predictive Values (PPV) for clinical reactivity to the specific allergen challenge. |
| |
Print |
| Allergen Profile, Pediatric |
| |
| Includes: |
Includes a Total IgE along with the following specific IgE allergens: • Foods: Egg White, Fish (Cod), Milk, Peanut, Soybean, Wheat • Miscellaneous: Cat dander, Cockroach, Dog dander, Alternaria alternata, House dust mites: D. farinae and D. pteronyssius |
| |
| CPT: |
82785, 86003 (x12) |
| |
| Alternate Name: |
Pediatric Allergen Profile |
| |
| Methodology: |
ImmunoCAP (FEIA) |
| |
| Testing Schedule: |
Routine, 4-6 times per week |
| |
| Report Available: |
3-5 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
4 mL serum |
| |
| Container: |
2 Gold top (serum separator) tubes |
| |
| Special Instructions and/or Comments: |
| Refrigerate |
| |
| Reference Range: |
• Total IgE: See individual test listing • Specific IgE Allergens: See chart below | Class | IgE ku/L | Interpretation | | 0 | <0.10 | Negative | | 0/1 | 0.10-0.35 | Borderline | | 1 | 0.35-0.69 | Equivocal | | 2 | 0.70-3.4 | Positive | | 3 | 3.5-17.4 | Positive | | 4 | 17.5-49.9 | Strongly Positive | | 5 | 50.0-100.0 | Strongly Positive | | 6 | >100.0 | Strongly Positive |
|
| |
| Clinical Utility: |
| Allergen specific IgE levels (kU/L) provide 95% Positive Predictive Values (PPV) for clinical reactivity to the specific allergen challenge. |
| |
Print |
| Allergen Profile, Venom |
| |
| Includes: |
Includes a Total IgE along with the following specific IgE allergens: • Common Wasp/Yellow Jacket, European Hornet, Honey Bee, Paper Wasp, Yellow Hornet, White faced Hornet |
| |
| CPT: |
82785, 86003 (x6) |
| |
| Alternate Name: |
Venom Allergen Profile |
| |
| Methodology: |
ImmunoCAP (FEIA) |
| |
| Testing Schedule: |
Routine, 4-6 times per week |
| |
| Report Available: |
3-5 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
4 mL serum |
| |
| Container: |
2 Gold top (serum separator) tubes |
| |
| Special Instructions and/or Comments: |
| Refrigerate |
| |
| Reference Range: |
• Total IgE: See individual test listing • Specific IgE Allergens: See chart below | Class | IgE ku/L | Interpretation | | 0 | <0.10 | Negative | | 0/1 | 0.10-0.35 | Borderline | | 1 | 0.35-0.69 | Equivocal | | 2 | 0.70-3.4 | Positive | | 3 | 3.5-17.4 | Positive | | 4 | 17.5-49.9 | Strongly Positive | | 5 | 50.0-100.0 | Strongly Positive | | 6 | >100.0 | Strongly Positive |
|
| |
| Clinical Utility: |
| Useful for allergen specific IgE levels (kU/L) provide 95% Positive Predictive Values (PPV) for clinical reactivity to the specific allergen challenge. |
| |
Print |
| Allergen Testing, General |
| |
| Includes: |
HNL offers comprehensive allergen-specific IgE testing. Allergens can be requested in profiles or as individual tests from the following categories: • Animal epidermals and proteins • Drugs • Foods • Grass Pollens • Insects/Mites • Molds and yeasts • Occupational exposure • Tree pollens • Weed pollens Use test code “ALKIT” and send copy of script to Immunology Department |
| |
| CPT: |
86003 times each specific allergen tested |
| |
| Alternate Name: |
Allergy testing; RAST testing |
| |
| Methodology: |
ImmunoCAP (FEIA) |
| |
| Testing Schedule: |
Routine, 4-6 times per week |
| |
| Report Available: |
3-5 days |
| |
| Specimen Requirements: |
| Collection: |
Collect 1 Gold top (serum separator) tube for every 7 single allergens requested |
| |
| Special Instructions and/or Comments: |
Refrigerate NOTE: A Total IgE level is not included and if requested, must be ordered separately. |
| |
| Reference Range: |
Specific IgE Allergens | Class | IgE ku/L | Interpretation | | 0 | <0.10 | Negative | | 0/1 | 0.10-0.35 | Borderline | | 1 | 0.35-0.69 | Equivocal | | 2 | 0.70-3.4 | Positive | | 3 | 3.5-17.4 | Positive | | 4 | 17.5-49.9 | Strongly Positive | | 5 | 50.0-100.0 | Strongly Positive | | 6 | >100.0 | Strongly Positive |
|
| |
| Clinical Utility: |
| Useful for allergen specific IgE levels (kU/L) provide 95% Positive Predictive Values (PPV) for clinical reactivity to the specific allergen challenge. |
| |
Print |
| ALP |
| |
| See Alkaline Phosphatase, Total, Serum |
Print |
| ALP Isoenzymes |
| |
| See Alkaline Phosphatase, Isoenzymes |
Print |
| 3-alpha, 17-beta Androstanediol lucuronide |
| |
| See Androstanediol Glucuronide |
Print |
| Alpha Fetoglobulin |
| |
| See Alpha-Fetoprotein, Tumor Marker |
Print |
| Alpha-Fetoprotein, Triple Screen |
| |
| See Triple Screen, Maternal Serum |
Print |
| Alpha-Fetoprotein, Tumor Marker |
| |
| CPT: |
82105 |
| |
| Alternate Name: |
• AFP • Alpha 1 Fetoprotein • Alpha Fetoglobulin |
| |
| Methodology: |
Chemiluminescent Immunoassay |
| |
| Testing Schedule: |
Routine, 2 times per week |
| |
| Report Available: |
3-5 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Special Instructions and/or Comments: |
| Testing is for males and non-pregnant females only. |
| |
| Reference Range: |
• Normal = <6.0ng/mL • Equivocal/indeterminate = 6.0-10.9ng/mL • Elevated = >10.9 ng/mL |
| |
| Clinical Utility: |
| Useful for monitoring the course of liver or testicular cancer, patient response to treatment, and disease recurrence. Alpha-fetoprotein (AFP) is elevated in the serum of more than 70% of patients with hepatocellular carcinoma (HCC) and 70% of patients with non-seminomatous testicular carcinoma. In non-seminomatous testicular carcinoma, tumor recurrence is often accompanied by a rise in AFP. THIS TEST SHOULD NOT BE USED FOR SCREENING NEURAL TUBE AND OTHER BIRTH DEFECTS. |
| |
Print |
| Alpha-Lipoprotein Cholesterol |
| |
| See HDL Cholesterol, Direct |
Print |
| Alpha Subunit |
| |
| CPT: |
83519 |
| |
| Alternate Name: |
Alpha Subunit of Pituitary Glycoprotein Hormones; PGH |
| |
| Methodology: |
ICOMA |
| |
| Testing Schedule: |
Routine, 2 times per week |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Special Instructions and/or Comments: |
| Centrifuge, transfer to plastic aliquot tube and freeze. Once frozen, transport specimen submerged in dry ice. |
| |
| Reference Range: |
| Accompanies Report |
| |
| Clinical Utility: |
| Useful for an adjunct in the diagnosis of pituitary tumors and as part of the follow-up of treated pituitary tumor patients. This test coul d also be used for the differential diagnosis of TSH secreting pituitary tumor versus thyroid hormone resistane. |
| |
Print |
| Alpha Subunit of Pituitary Glycoprotein Hormones |
| |
| See Alpha Subunit |
Print |
| Alpha1-Antitrypsin, Genotyping Profile |
| |
| Includes: |
• Alpha-1-Antitrypsin, Quantitative • Alpha-1-Antitrypsin, Genotype • Reflexes to Alpha-1-Antitrypsin, Phenotype if results of genotype are discordant |
| |
| CPT: |
82103, 83890, 83896 X2, 83898 X2, 93912, and if appropriate 82104 (A1A phenotype) |
| |
| Alternate Name: |
• A1A Genotype • Prolastin |
| |
| Methodology: |
Polymerase Chain Reaction (PCR), Nephelometry, Reflexed when appropriate Isoclectric focusing |
| |
| Testing Schedule: |
Routine, Mon-Fri. ONLY |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1.0 mL serum AND 3 mL whole blood |
| |
| Container: |
Gold top (serum separator) tube AND Lavender top (EDTA) tube |
| |
| Special Instructions and/or Comments: |
• Both whole blood and serum are required for this test • Store whole blood at room temperature • Store serum refrigerated |
| |
| Reference Range: |
| Accompanies Report |
| |
| Clinical Utility: |
| Useful for determining the specific allelic variant (genotyping) for prognosis and genetic counseling. |
| |
Print |
| Alpha1-Antitrypsin, Phenotype |
| |
| Includes: |
• Alpha1-Antitrypsin, Quantitative • Alpha1-Antitrypsin, Phenotype |
| |
| CPT: |
82103, 82104 |
| |
| Alternate Name: |
• A1AN Pi; • P-type |
| |
| Methodology: |
Isoelectric Focusing Nephelometry |
| |
| Testing Schedule: |
Routine, 2 times per week |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1.0 mL serum |
| |
| Container: |
Gold op (serum separator) tube |
| |
| Reference Range: |
Alpha-1-antitrypsin: 100-190 mg/dL Alpha-1-Antitrypsin Penotyping: Most normal individuals have the M phenotype (M, M1, or M2). Over 99% of M phenotypes are genotypically MM. In the absence of family studies, the phenotype (M) and quantitative level can be used to infer the genotype (MM). The most common alleles associated with a quantitative deficiency are Z and S. The reports for the rare alleles will indicate whether or not they have been associated with reduced quantitative levels |
| |
| Clinical Utility: |
| Useful for identification of homozygous and heterozygous phenotypes of the A1A deficiency. |
| |
Print |
| Alpha1-Antitrypsin, Quantitative |
| |
| CPT: |
82103 |
| |
| Alternate Name: |
• A1-Antitrypsin; A1AT • AAT •Alpha1 Protease Inhibitor |
| |
| Methodology: |
Rate Nephelometry |
| |
| Testing Schedule: |
Routine, 2 times per week |
| |
| Report Available: |
3-5 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Reference Range: |
| 90-200 mg/dL |
| |
| Clinical Utility: |
| Useful in the detection of hereditary diseases in the production of alpha-1-antitrypsin (AAT). Decreased or nearly absent levels of AAT can be a factor in chronic obstructive lung disease and liver disease. An increased prevalence of non-MM phenotypes is found with cryptogenic cirrhosis and with chronic active hepatitis (CAH). Cirrhosis in a child should raise consideration of AAT deficiency or Wilson’s disease. Diagnosis of inflammatory states, if elevated, e.g., rheumatoid arthritis, bacterial infection, vasculitis and neoplasia. |
| |
Print |
| Alpha1-Fetoprotein |
| |
| See Alpha-Fetoprotein, Tumor Marker |
Print |
| Alpha1 Protease Inhibitor |
| |
| See Alpha1-Antitrypsin, Quantitative |
Print |
| Alpha-Fetoprotien, Maternal Serum |
| |
| CPT: |
82105 |
| |
| Alternate Name: |
• MsAFP • AFP Neual Tube Defects • Maternal Screening, single marker |
| |
| Methodology: |
Two site Immunoenzymatic (Sandwich) Assay |
| |
| Testing Schedule: |
Daily, Mon-Sat, routine |
| |
| Report Available: |
3-5 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top, (serum separator) tube NOTE: Specimen must be accompanied by a completed “Second Trimester Maternal Screening Alpha-fetoprotein (AFP)/Quad Screen Patient Information Sheet”. All 10 questions must be completed. |
| |
| Collection: |
DO NOT draw after amniocentesis as this could affect results Gestational age must be between 12 and 22 weeks; 16 - 18 weeks is optimal. System defaults to ultrasound dating when provided. |
| |
| Reference Range: |
NEURAL TUBE DEFECTS • An AFP multiple of the medial (MoM) < 2.5 as reported as screen negative • AFP MoM > 2.5 (singleton pregnancies) • > 5.33 (twin gestation) are reported as screen positive. An interpretative report will be provided |
| |
| Clinical Utility: |
| Useful for prenatal screening for open neural tube defect. |
| |
Print |
| Alprazolam |
| |
| Includes: |
Identification and quantitation of alprazolam and alpha-hydroxyalprazolam in whole blood, serum or plasma |
| |
| CPT: |
80154 |
| |
| Alternate Name: |
Xanax |
| |
| Methodology: |
LC/MS/MS |
| |
| Testing Schedule: |
Once per week |
| |
| Report Available: |
3-5 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
2 mL whole blood, serum or plasma Minimum Volume: 1 mL |
| |
| Container: |
Gray top, Red top or lavendar top tube |
| |
| Special Instructions and/or Comments: |
| • Refrigerate |
| |
| Reference Range: |
Alprazolam Therapeutic...........10-100 ng/mL Alpha-hydroxyalprazolam Not established, however, has 65% pharmacological activity of alprazolam |
| |
| Clinical Utility: |
| Identification and quantitation of use or abuse of alprazolam. |
| |
Print |
| Aluminum, Serum |
| |
| CPT: |
82108 |
| |
| Methodology: |
Inductively Coupled Plasma- Mass Spectrometry (ICP_MS) |
| |
| Testing Schedule: |
Routine, 5 times per week |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
2 mL serum |
| |
| Container: |
Royal Blue top trace metal tube, red label |
| |
| Special Instructions and/or Comments: |
• Centrifuge, pour serum into metal free, acid washed vial and freeze. • DO NOT insert a pipette into the serum to accomplish transfer. • DO NOT ream the specimen with a wooden stick. • Specimen will only be accepted in vials labeled with “metal free” labels. |
| |
| Reference Range: |
| 0-6 ng/mL |
| |
| Clinical Utility: |
| Monitoring patients undergoing dialysis for aluminum toxicity. |
| |
Print |
| AMA |
| |
| See Mitochondrial Autoantibody |
Print |
| Amikacin Peak: |
| |
| CPT: |
80150 |
| |
| Methodology: |
Immunoassay (IA) |
| |
| Testing Schedule: |
Routine, daily |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum or plasma |
| |
| Container: |
Red top or SST tube, or EDTA lavendar |
| |
| Collection: |
Peak: Collect 30 minutes post infusion of IV dose. Trough: Collect 30 minutes before next dose. |
| |
| Special Instructions and/or Comments: |
Centrifuge, transfer serum or plasma to plastic aliquot tube and freeze if delay in analysis will be more than 8 hours Failure to freeze samples containing additional antibiotics may results in falsely low amikacin levels due to in vitro inactivation. |
| |
| Reference Range: |
Peak:.......Therapeutic:........20-25 µg/mL Trough:...Therapeutic:..........5-10 µg/mL |
| |
| Clinical Utility: |
Amikacin is effective in the treatment of serious gram-negative infections and is particularly useful in those strains resistant to other aminoglycosides. Monitoring serum/plasma concentrations of amikacin is useful because of the narrow margin between therapeutic effectiveness and toxicity. |
| |
Print |
| AmikacinTrough: |
| |
| CPT: |
80150 |
| |
| Methodology: |
Immunoassay (IA) |
| |
| Testing Schedule: |
Routine, daily |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum or plasma |
| |
| Container: |
Red top or SST tube, or EDTA lavendar |
| |
| Collection: |
Peak: Collect 30 minutes post infusion of IV dose. Trough: Collect 30 minutes before next dose. |
| |
| Special Instructions and/or Comments: |
Centrifuge, transfer serum or plasma to plastic aliquot tube and freeze if delay in analysis will be more than 8 hours Failure to freeze samples containing additional antibiotics may results in falsely low amikacin levels due to in vitro inactivation. |
| |
| Reference Range: |
Peak: Therapeutic..................20-25 µg/mL Trough: Therapeutic:..............5-10 µg/mL |
| |
| Clinical Utility: |
Amikacin is effective in the treatment of serious gram-negative infections and is particularly useful in those strains resistant to other aminoglycosides. Monitoring serum/plasma concentrations of amikacin is useful because of the narrow margin between therapeutic effectiveness and toxicity. |
| |
Print |
| Amino Acids, Plasma, |
| |
| CPT: |
82139 |
| |
| Methodology: |
Ion-Exchange Chromatography |
| |
| Testing Schedule: |
Routine, daily |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1.0 mL plasma |
| |
| Container: |
Green top (sodium heparin) tube |
| |
| Collection: |
Must be drawn from a fasting patient (4 hours or more in infants) |
| |
| Special Instructions and/or Comments: |
• Centrifuge, transfer to plastic aliquot tube and freeze. • Once frozen, transport specimen submerged in dry ice. |
| |
| Reference Range: |
Age dependent reference values accompany report |
| |
| Clinical Utility: |
| Useful for evaluating patients with possible inborn errors of metabolism. Amino acid analysis may also have clinical importance in the evaluation of several acquired conditions, including endocrine disorders, liver diseases, muscle diseases, neoplastic diseases, neurological disorders, nutritional disturbances, renal failure and burns. |
| |
Print |
| Amino Acids, Quantitative, Urine |
| |
| CPT: |
82139 |
| |
| Methodology: |
Ion-Exchange Chromatography, Quantitative |
| |
| Testing Schedule: |
Routine, daily |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
2 mL random urine |
| |
| Container: |
Plastic urine container |
| |
| Special Instructions and/or Comments: |
• Freeze specimen in plastic container. DO NOT use glass. • Once frozen, transport specimen submerged in dry ice. |
| |
| Reference Range: |
Age dependent reference values accompany report |
| |
| Clinical Utility: |
Useful for evaluating patients with possible inborn errors of metabolism. Amino acid analysis may also have clinical importance in the evaluation of several acquired conditions, including endocrine disorders, liver diseases, muscle diseases, neoplastic diseases, neurological disorders, nutritional disturbances, renal failure and burns. |
| |
Print |
| Aminolevulinic Acid (ALA) Urine, 24-Hour |
| |
| Includes: |
• Volume Measurement • Collection Period • Aminolevulinic Acid, Urine |
| |
| CPT: |
81050, 82135 |
| |
| Alternate Name: |
• ALA, Urine • Delta ALA, Urine |
| |
| Methodology: |
Colorimetry |
| |
| Testing Schedule: |
Routine, 1 time per week |
| |
| Report Available: |
7-10 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
25 mL aliquot of a well mixed 24-Hour urine collection. |
| |
| Container: |
• 24-Hour plastic urine container • Add 25 mL of 50% acetic acid at start of collection. |
| |
| Collection: |
• Instruct the patient to void at the beginning of the collection period and discard the specimen. Instruct the patient not to void directly into container. • Collect all urine, including the final specimen voided at the end of collection period. • Refrigerate during collection. • Transport to the laboratory promptly. • Container must be labeled with the patient’s name. |
| |
| Special Instructions and/or Comments: |
• Random specimens are accepted, but 24-Hour collections are preferred. • If processing and aliquoting specimen, protect from light by wrapping the entire aliquot tube with aluminum foil, or use 60 mL amber urine container. |
| |
| Reference Range: |
• 0-8 Months:.....................Not established • 9 months - 5 years:.......... < 50 mcmol/L • > 6 years:......................... < 57 mcmol/24 hr |
| |
| Clinical Utility: |
| Useful for the differential diagosis of the various Porphyrias or indicating lead poisoning in children |
| |
Print |
| Aminophylline |
| |
| See Theophylline, Serum |
Print |
| Amiodarone |
| |
| Includes: |
• Amiodarone • Desethylamiodarone |
| |
| CPT: |
82492 |
| |
| Alternate Name: |
Cordarone® |
| |
| Methodology: |
High Performance Liquid Chromatography (HPLC) |
| |
| Testing Schedule: |
Routine, 2 times per week |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
2 mL serum |
| |
| Container: |
Red top tube, no serum separator |
| |
| Special Instructions and/or Comments: |
• Centrifuge, transfer to plastic aliquot tube and freeze. • Once frozen, transport specimen submerged in dry ice. • Aminodarone peak concentrations are reached 3-7 hours following oral administration. Half life of amiodarone is 26-107 days and shows a biphasic elimination pattern. |
| |
| Reference Range: |
• Amiodarone: Therapeutic.....................0.5-2.0 µg/mL • Desethylamiodarone: Therapeutic:....................0.25-3.5 µg/mL |
| |
| Clinical Utility: |
| Useful for monitoring adequacy of blood concentration during amiodarone therapy and to evaluate patient compliance. |
| |
Print |
| Amitriptyline |
| |
| Includes: |
• Amitriptyline • Nortriptyline |
| |
| CPT: |
80152, 80182 |
| |
| Alternate Name: |
Elavil®; Triavil® |
| |
| Methodology: |
High Pressure Liquid Chromatography (HPLC) |
| |
| Testing Schedule: |
Routine, daily |
| |
| Report Available: |
3-5 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
3 mL serum |
| |
| Container: |
Red top tube (NO serum separator) |
| |
| Collection: |
Collect 12 hours after last dose. |
| |
| Special Instructions and/or Comments: |
• Separate plasma from cells within 2 hours of drawing • Refrigerate |
| |
| Reference Range: |
Amitriptyline & Nortriptyline: • Total Therapeutic:....................80-200 ng/mL • Total Toxic Concentration.......>1000 ng/mL Nortriptyline only: • Therapeutic:......................70-170 ng/mL • Toxic Concentration .........>500 ng/mL |
| |
| Clinical Utility: |
| Useful for monitoring adequacy of blood concentration during amitriptyline therapy and to evaluate patient compliance. |
| |
Print |
| Ammonia, Plasma |
| |
| CPT: |
82140 |
| |
| Alternate Name: |
• Blood Ammonia • Blood NH3 • Blood NH4 • NH3; • NH4 |
| |
| Methodology: |
Enzymatic |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
2 mL plasma |
| |
| Container: |
Lavender top (EDTA) tube |
| |
| Collection: |
• Fill tube completely. • Collect anaerobically. • DO NOT uncap tube. • Place specimen on wet ice and transport to the laboratory immediately. |
| |
| Special Instructions and/or Comments: |
| If testing cannot be performed within 15 minutes of collection, centrifuge specimen, transfer plasma to plastic aliquot tube and freeze. Once frozen, transport specimen submerged in dry ice. |
| |
| Reference Range: |
| 5 - 35 µmol/L |
| |
| Critical Values: |
| >100 µmol/L |
| |
| Clinical Utility: |
| Used in the evaluation of hepatic coma and comas of unknown origin, neurological deterioration, urea cycle disorders, hepatic disease, encephalopathy and Reye’s syndrome. |
| |
Print |
| Amniotic Fluid Analysis for Erythroblastosis Fetalis Amniotic Fluid Bilirubin |
| |
| See Bilirubin, Amniotic Fluid |
Print |
| Amniotic Fluid, Chromosome Analysis |
| |
| See Chromosome Analysis, Amniotic Fluid |
Print |
| Amoebic Antibody |
| |
| See Entamoeba histolytica Antibody |
Print |
| Amoxapine |
| |
| Includes: |
• Amoxapine • 8-Hydroxyamoxapine • Combined Total |
| |
| CPT: |
82492 |
| |
| Alternate Name: |
Asendin® |
| |
| Methodology: |
High Performance Liquid Chromatography (HPLC) with Ultraviolet (UV) Detection |
| |
| Testing Schedule: |
Routine, 1 time per week |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
2 mL serum |
| |
| Container: |
Red top tube, no serum separator |
| |
| Special Instructions and/or Comments: |
| Refrigerate |
| |
| Reference Range: |
| Combined Total:.............200-400 ng/mL |
| |
| Clinical Utility: |
| Useful for monitoring patient compliance. |
| |
Print |
| Amphetamines, Qualitative, Urine |
| |
| Includes: |
• Amphetamine • Methamphetamine • Phentermine |
| |
| CPT: |
80101 |
| |
| Alternate Name: |
Amphetamine; Methamphetamine |
| |
| Methodology: |
Immunoassay (IA) |
| |
| Testing Schedule: |
Routine, daily |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
5 mL random urine |
| |
| Container: |
Plastic urine container |
| |
| Special Instructions and/or Comments: |
| If for forensic or legal purposes, submit specimen with a completed Drug Testing Request and Chain-of-Custody (HNL-53) Form or Blood Alcohol Toxicology Request/Chain-of-Custody (LAB-32) Form. |
| |
| Reference Range: |
None present NOTE: Confirmation by GC/MS (Gas Chromatography/ Mass Spectrometry) available upon request. Contact Customer Care 610-402-8170 for instructions. |
| |
| Clinical Utility: |
| A qualitative screen useful for detection of drug abuse/use of amphetamines. Confirmation of a positive screening result by GC/MS is strongly recommended. |
| |
Print |
| Amphetamines, Panel in Blood |
| |
| Includes: |
• Identification and quantification of: • Amphetamine • Methamphetamine • Phentermine • Ephedrine • Pseudoephedrine • Phenylpropanolamine • MDMA • MDA • PMA • MDEA |
| |
| CPT: |
82145 |
| |
| Methodology: |
GC/MS |
| |
| Testing Schedule: |
Routine, once per week |
| |
| Report Available: |
1-2 weeks |
| |
| Specimen Requirements: |
| Minimum Volume: |
2 mL whole blood |
| |
| Container: |
Gray Top (sodium fluoride) or Lavendar Top (EDTA) |
| |
| Collection: |
If for forensic or legal purposes, submit in plastic evidence bag with Chain-of-Custody Form. |
| |
| Reference Range: |
• Amphetamine..................Therapeutic 30-110ng/ml • Methamphetamine..........Therapeutic 10-50ng/ml • Phentermine....................Therapeutic 90-500ng/ml • Phenylpropanolamine.....Therapeutic 30-480ng/ml • Ephedrine........................Therapeutic 68-100ng/ml • Pseudoephedrine.............Therapeutic 500-770ng/ml • MDA...............................None Detected • MDMA............................None Detected • PMMA.............................None Detected • MDEA.............................None Detected |
| |
| Clinical Utility: |
| Useful for the specific identification and quantitation of amphetamines in blood. |
| |
Print |
| Amphetamines, Urine, GCMS, |
| |
| Includes: |
• Identification and quantitation by GCMS: • Amphetamine • Methamphetamine • Phentermine • Methylenedioxymethamphetamine (MDMA) • Methylenedioxyamphetamine (MDA) • Methylenedioxyethylamphetamine (MDEA) |
| |
| CPT: |
82145 |
| |
| Methodology: |
Gas Chromatography/Mass Spectroscopy (GC/MS) |
| |
| Testing Schedule: |
3 times/week |
| |
| Report Available: |
3-5 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
5 mL random urine |
| |
| Container: |
Plastic urine container |
| |
| Special Instructions and/or Comments: |
| If for forensic or legal purposes, submit specimen with a completed Drug Testing Request and Chain-of-Custody (HNL-53) Form or Blood Alcohol oxicology Request/Chain-of-Custody (LAB-32) Form. |
| |
| Reference Range: |
| None present |
| |
| Clinical Utility: |
| Useful for detection and positive identification of specific amphetamine compounds in urine. |
| |
Print |
| Amylase, Serum |
| |
| CPT: |
82150 |
| |
| Methodology: |
HNL: Rate LPP: Bichromatic Rate |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Reference Range: |
• 30-110 units/L • Pediatrics: Newborn serum shows little, if any, amylase activity. Much of this activity is apparently of salivary origin. Markedly low values may not rise to adult values until the end of the first year of life. |
| |
| Critical Values: |
| >300 units/L |
| |
| Clinical Utility: |
| Useful in the evaluation of disorders of the pancreas. |
| |
Print |
| Amylase, Body Fluid |
| |
| CPT: |
82150 |
| |
| Alternate Name: |
• Body Fluid Amylase • Cyst Fluid Amylase |
| |
| Methodology: |
HNL Rate |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL body fluid |
| |
| Container: |
Red top tube, no serum separator |
| |
| Reference Range: |
| Not established, must be interpreted with clinical findings. |
| |
Print |
| Amylase Clearance/ Creatinine Clearance Ratio, Random Urine |
| |
| Includes: |
• Amylase, Serum • Amylase, Urine • Creatinine, Serum • Creatinine, Urine • Glomerular Filtration Rate Calculation (GFR) |
| |
| CPT: |
82150 (x2), 82575 |
| |
| Methodology: |
See individual test listings |
| |
| Testing Schedule: |
Routine, daily |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
Random urine AND 1 mL serum |
| |
| Container: |
Plastic urine container AND gold top (serum separator) tube |
| |
| Special Instructions and/or Comments: |
• Refrigerate • GFR Calculation is not performed when: • patient is < 20 years of age. • a renal steady state is not present. • sex of patient is unkown. |
| |
| Reference Range: |
• Amylase, Serum...........................30-110 units/L • Amylase, Random Urine:.............32-641 units/L • Creatinine, Serum: • > 14 years.............0.7-1.5 mg/dL • See individual test listings for pediatric ranges • Creatinine, Random Urine:...........50-200 mg/dL • Ratio...............................................1.3-4.3 % • Glomerular Filtration Rate: mL/min per 1.73 m2 • Normal Function or Mild Renal Disease (if clinically at risk):..............................> 60 • Moderately Decreased:.................30-59 • Severly Decreased:.......................15-29 • Renal Failure:.........................<15 NOTE: African-American GFR: multiply reported GFR by 1.210 |
| |
| Critical Values: |
• Amylase, Serum: ..............>300 U/L • Creatinine, Serum:............>5.0 mg/dL |
| |
| Clinical Utility: |
| Evaluate the clearance of amylase by the kidneys. Assist in the evaluation of acute pancreatitis. |
| |
Print |
| Amylase/Creatinine Ratio, Random Urine |
| |
| CPT: |
82150, 82570 |
| |
| Alternate Name: |
Urine Amylase/Creatinine Ratio |
| |
| Methodology: |
See individual test listings |
| |
| Testing Schedule: |
Routine, daily |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
5 mL urine |
| |
| Container: |
Plastic urine container |
| |
| Collection: |
Freshly voided random urine. |
| |
| Special Instructions and/or Comments: |
| Refrigerate |
| |
| Reference Range: |
• Amylase, Random Urine:............32-641 units/L • Creatinine, Random Urine:.........50-200 mg/dL • Ratio:...........................................0.01-0.40 units/mg |
| |
| Clinical Utility: |
Ratio is utilized to assist in the evaluation of pancreatic diseases. |
| |
Print |
| Amylase Isoenzymes |
| |
| See Amylase, Pancreatic |
Print |
| Amylase, Pancreatic |
| |
| CPT: |
82150 |
| |
| Methodology: |
Automated Monoclonal Antibody Technique |
| |
| Testing Schedule: |
Routine, daily |
| |
| Report Available: |
3-5 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Special Instructions and/or Comments: |
| Centrifuge, transfer to plastic aliquot tube and freeze. Once frozen, transport specimen submerged in dry ice. |
| |
| Reference Range: |
| 11-54 U/L |
| |
| Clinical Utility: |
| Useful for diagnosing acute pancreatitis. |
| |
Print |
| Amylase, Urine; Random: |
| |
| CPT: |
82150 |
| |
| Methodology: |
Rate |
| |
| Testing Schedule: |
Routine, daily |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
5 mL random urine |
| |
| Container: |
Plastic urine container |
| |
| Collection: |
Random |
| |
| Special Instructions and/or Comments: |
| Transport to the laboratory promptly. |
| |
| Reference Range: |
| • Amylase, Random Urine: 32-641 units/L |
| |
| Clinical Utility: |
| Used in the evaluation of disorders of the pancreas. |
| |
Print |
| ANA |
| |
| See Antinuclear Antibody Screen |
Print |
| ANA Titer |
| |
| See Antinuclear Antibody Screen |
Print |
| ANA Panel |
| |
| See Antinuclear Antibody Profile, Comprehensive |
Print |
| Anaerobic Culture, Actinomycosis |
| |
| See Culture, Actinomyces, Anaerobic |
Print |
| Anaerobic/Aerobic Culture |
| |
| See Culture, Anaerobic/Aerobic |
Print |
| Anafranil® |
| |
| See Clomipramine |
Print |
| ANAP |
| |
| See Antinuclear Antibody Profile, Comprehensive |
Print |
| ANCA |
| |
| See Neutrophil Cytoplasmic Autoantibody Profile |
Print |
| Androstanediol Glucuronide |
| |
| CPT: |
82154 |
| |
| Alternate Name: |
3-alpha, 17-beta Androstanediol Glucuronide |
| |
| Methodology: |
Radioimmunoassay (RIA) after hydrolysis of Glucuronide and Chromatography |
| |
| Testing Schedule: |
Routine, 1 time per week |
| |
| Report Available: |
7-10 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Red top tube, (no serum separator) tube |
| |
| Reference Range: |
• Prepubertal Children 0-10y ........< 5-42 ng/dL • Adult Males:...................................190-900 ng/mL • Adult Females:...............................35-200 ng/mL |
| |
| Clinical Utility: |
| Elevated androstanediol glucuronide levels indicate increased DHT production. |
| |
Print |
| Androstenedione |
| |
| CPT: |
82157 |
| |
| Methodology: |
LC-MS/MS (Liquid Chromatography/Tandem Mass Spectrometry) |
| |
| Testing Schedule: |
Routine, 2 times per week |
| |
| Report Available: |
3-5 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL frozen serum |
| |
| Container: |
Red top tube, no serum separator |
| |
| Special Instructions and/or Comments: |
| • Centrifuge, transfer serum to plastic vial and freeze. • Once frozen, transport specimen submerged in dry ice. |
| |
| Reference Range: |
PEDIATRICS* Premature infants 26-28 weeks, day 4: 92-282 ng/dL Premature infants 31-35 weeks, day 4: 80-446 ng/dL Full-Term infants 1-7 days: 20-290 ng/dL 1 month - 1 year: 6-68 ng/dL Males*| Tanner Stages | Age (years) | Reference Range (ng/dL) | | Stage I (prepubertal) | < 9.8 | <15-50 | | Stage II | 9.8-14.5 | 31-65 | | Stage III | 10.7-15.4 | 50-100 | | Stage IV | 11.8-16.2 | 48-140 | | Stage V | 12.8-17.3 | 65-210 |
Females*| Tanner Stages | Age (years) | Reference Range (ng/dL) | | Stage I (prepubertal) | < 9.2 | <15-50 | | Stage II | 9.2-13.7 | 42-100 | | Stage III | 10.0-14.4 | 80-190 | | Stage IV | 10.7-15.6 | 77-225 | | Stage V | 11.8-18.6 | 80-240 |
ADULTS • Male: ..........................40-150 ng/dL • Female: ......................30-200 ng/dL |
| |
| Clinical Utility: |
| Useful for diagnosis and differnctial diagnosis of Hyperandrogenism (in conjunction with measurements of other sex steroids). Can also be used to diagnose CAH (Congenital Adrenal Hyperplasia) in conjunction with measurement of other androgenic precursosrs and to monitor CAH treatment. |
| |
Print |
| Angiotensin-1-Converting Enzyme, Cerebrospinal Fluid |
| |
| CPT: |
82164 |
| |
| Alternate Name: |
• A1CE • ACE |
| |
| Methodology: |
Kinetic Spectrophotometry |
| |
| Testing Schedule: |
Routine, daily |
| |
| Report Available: |
7-10 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL cerebrospinal fluid |
| |
| Collection: |
Sterile conical tube |
| |
| Special Instructions and/or Comments: |
| Refrigerate |
| |
| Reference Range: |
| < 15 u/L |
| |
| Clinical Utility: |
| Useful for evaluation of patients with suspected sarcoidosis. |
| |
Print |
| Angiotensin-1-Converting Enzyme, Serum |
| |
| CPT: |
82164 |
| |
| Alternate Name: |
A1CE; ACE |
| |
| Methodology: |
Spectrophotometry |
| |
| Testing Schedule: |
Routine, daily |
| |
| Report Available: |
3-5 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Collection: |
Fasting patient preferred. |
| |
| Special Instructions and/or Comments: |
• Centrifuge, transfer to plastic aliquot tube and freeze. • Once frozen, transport specimen submerged in dry ice. |
| |
| Reference Range: |
The reference interval for children and adolescents may be as much as 50% higher than specimens for adults. (Rodriguez GE Shin BC, Abernathy RS, Kendig EL Jr: Serum angiotensin-converting enzyme activity in normal children and in those with sarcoidosis. J Pediatr 1981;99:68-72; Package Insert: ALPCO Angiotensin Converting Enzyme Reagent, American Laboratory Products Company, Windham, NH, 2001 July) .............................8-53 U/L |
| |
| Clinical Utility: |
| Useful for evaluation of patients with suspected Sarcoidosis. |
| |
Print |
| Anti-A Titer |
| |
| See Isoagglutinin Titer, Anti-A and/or Anti-B |
Print |
| Anti-Adrenal Antibody |
| |
| See Adrenal Autoantibody |
Print |
| Anti-B Titer |
| |
| See Isoagglutinin Titer, Anti-Aand/or Anti-B |
Print |
| Antibiotic Sensitivity |
| |
| See individual culture listing |
Print |
| Antibiotic-Associated Colitis Toxin Test |
| |
| See Clostridium difficile Toxin A/B Assay |
Print |
| Antibody Identification, Red Blood Cells |
| |
| See Type and Antibody Screen |
Print |
| Antibody Screen |
| |
| See Type and Antibody Screen |
Print |
| Antibody Screening Test |
| |
| See Type and Antibody Screen |
Print |
| Antibody Titer |
| |
| Includes: |
NOTE: This test is primarily used for prenatal testing. It is a semiquantitative technique used to estimate the strengths of an antibody. All clinically significant alloantibodies known to cause hemolytic disease of the newborn should be titered. The results of the titration are used to determine whether and when to initiate other means of fetal monitoring, such as amniocentesis, percutaneous umbilical cord sampling, or ultrasonography. • Antibody Titer • Reflexed when appropriate: • ABO • Antibody Screen • Antibody Identification • Rh (D) |
| |
| CPT: |
86886, Reflexed when appropriate: 86900, 86850, 86870, 86901 |
| |
| Related Information: |
Prenatal Testing |
| |
| Methodology: |
See individual test listings |
| |
| Testing Schedule: |
Routine, Monday-Friday only |
| |
| Report Available: |
1-3 days |
| |
| Specimen Requirements: |
| Container: |
4 mL plasma Container: Pink top (EDTA) tube |
| |
| Special Instructions and/or Comments: |
| Non-hospitalized patients: Submit specimen with a completed Blood Bank Requisition (LAB-04) Form. An initial Antibody Titer will be performed for all clinically significant antibodies having reactivity 1+ or greater detected in the Type and Antibody Screen test for prenatal testing. Subsequent titers should be requested by the physician. |
| |
| Reference Range: |
| Results are expressed as the reciprocal of highest serum dilution that causes macroscopic agglutination. A titer is reported as 32, not 1:32. A titer >8 is considered significant. In comparative studies, a difference in titer of at least three dilutions can be considered a significant difference. |
| |
Print |
| Antibody to Gastric Parietal Cells |
| |
| See Parietal Cell Autoantibody |
Print |
| Antibody to Native DNA |
| |
| See DNA Autoantibody, Double-Stranded |
Print |
| Anti-Cardiolipin G/A/M |
| |
| See Cardiolipin Autoantibody Profile |
Print |
| Anti-Centromere Antibody |
| |
| See Centromere Autoantibody |
Print |
| Anti-Desoxyribonuclease B |
| |
| See DNase B Antibody |
Print |
| Antidiuretic Hormone |
| |
| CPT: |
84588 |
| |
| Alternate Name: |
ADH; Arginine Vasopressin |
| |
| Methodology: |
Radioimmunoassay (RIA) |
| |
| Testing Schedule: |
Routine, 2 times per week |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
2 mL platelet poor plasma |
| |
| Container: |
Lavender top (EDTA) tube |
| |
| Collection: |
Patient should fast & thirst for 6 hours. No liquids, including water, are allowed. |
| |
| Special Instructions and/or Comments: |
• Transport to the laboratory immediately. • Must be processed and frozen immediately. • Collect blood in a lavender-top (EDTA) tube(s), and process 5 mL of EDTA whole blood as follows: • Spin down in a refrigerated centrifuge at approximately 1,000 x G (2,000 rpm for a 20-cm radius centrifuge) for 10 minutes. • Remove plasma, carefully avoiding the platelet/buffy coat. • Transfer 2 mL of EDTA platelet-poor plasma into a plastic aliquot tube and freeze. Once frozen, transport specimen submerged in dry ice. • Specimens frozen in glass vials are NOT acceptable. |
| |
| Reference Range: |
| <1.7 pg/mL |
| |
| Clinical Utility: |
| Useful for the diagnosis and characterization of diabetis insipidus. Can also be used to diagnose psychogenic water intoxication and cetopic arginine vasopressin production, particularly due to bronchogenic carcinoma. |
| |
Print |
| Anti-DNase B |
| |
| See DNase B Antibody |
Print |
| Anti-ds-DNA |
| |
| See DNA Autoantibody, Double-Stranded |
Print |
| Anti-Endomysial Antibody |
| |
| See Endomysial IgA Autoantibody |
Print |
| Anti-GAD Antibody |
| |
| See Glutamic Acid Decarboxylase Autoantibody |
Print |
| Anti-Gliadin Antibody Profile |
| |
| See Gliadin Autoantibody Profile |
Print |
| Antiglobulin Test, Indirect |
| |
| See Type and Antibody Screen |
Print |
| Anti-Glomerular Basement Membrane Antibody |
| |
| See Glomerular Basement Membrane Autoantibody |
Print |
| Anti-HAV, Total |
| |
| See Hepatitis A Antibody, Total |
Print |
| Anti-HBsAg |
| |
| See Hepatitis B Surface Antibody |
Print |
| Anti-HCV |
| |
| See Hepatitis C Antibody Profile |
Print |
| Anti-Histone Antibody |
| |
| See Histone Autoantibody |
Print |
| Anti-Hu Antibody |
| |
| See Neuronal Nuclear Autoantibody,Serum |
| See Neuronal Nuclear Autoantibody, Cerebrospinal Fluid |
Print |
| Anti-Human Globulin Test, Direct |
| |
| See Direct Coombs Test |
Print |
| Anti-Islet Cell Antibody |
| |
| See Islet Cell Autoantibody |
Print |
| Anti-La |
| |
| See Sjögren’s Autoantibody Profile |
Print |
| Anti-Mitochondrial Antibody |
| |
| See Mitochondrial Autoantibody |
Print |
| Anti-Thyroglobulin Autoantibody |
| |
| See Thyroglobulin Autoantibody |
| See Thyroglobulin Profile |
| See Thyroid Autoantibody Profile |
Print |
| Anti-TG Antibody |
| |
| See Thyroglobulin Autoantibody |
| See Thyroglobulin Profile |
| See Thyroid Autoantibody Profile |
Print |
| Antimony |
| |
| CPT: |
83018 |
| |
| Methodology: |
Inductively Coupled Plasma/Mass Spectrometry (ICP-MS) |
| |
| Testing Schedule: |
Routine, Monday-Friday only |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
2 mL serum |
| |
| Collection: |
Royal Blue top trace metal tube, red label |
| |
| Special Instructions and/or Comments: |
• Centrifuge, pour serum into metal free, acid washed vial and freeze. • DO NOT insert a pipette into the serum to accomplish transfer. • DO NOT ream the specimen with a wooden stick. • Specimen will only be accepted in vials labeled with “metal free” labels. |
| |
| Reference Range: |
• Reporting Limit:...................1.0 ng/mL • Reference Range:..................1.0 ng/Ml |
| |
| Clinical Utility: |
| Useful to access toxicity |
| |
Print |
| Antinuclear Antibody Profile |
| |
| See Antinuclear Antibody Profile, Comprehensive |
Print |
| Antinuclear Antibody Screen |
| |
| Includes: |
• Antinuclear Antibody Screen (ANA) • Reflexed when appropriate: • Titer and pattern of nuclear fluorescence on all positive screens |
| |
| CPT: |
86038, Reflexed when appropriate: 86039 |
| |
| Alternate Name: |
• ANA • ANA Titer • FANA • LE Prep |
| |
| Methodology: |
Enzyme immunoassay / indirect immunofluorescence |
| |
| Testing Schedule: |
Routine, 2 times per week |
| |
| Report Available: |
e: 3-5 days (may be extended if reflex testing required) |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Reference Range: |
| Negative: <1:40 |
| |
| Clinical Utility: |
Screening test for the detecion of antibodies to nuclear antigens. |
| |
Print |
| Antinuclear Antibody Screen with Reflex to Antinuclear Antibody Profile |
| |
| Includes: |
• Antinuclear Antibody Screen (ANA) • Reflexed when appropriate: • Titer and pattern of nuclear fluorescence on all positive screens • Reflexed on positive screens with titers >1:80: • DNA Autoantibody, Double Stranded • SS-A Autoantibody • SS-B Autoantibody • RNP Autoantibody • Sm Autoantibody • Scl-70 Autoantibody |
| |
| CPT: |
86038; Reflexed when appropriate 86039, 86225, 86235 (X5) |
| |
| Alternate Name: |
ANA Reflex; Reflex ANA |
| |
| Methodology: |
See individual test listings |
| |
| Testing Schedule: |
Routine, 2 times per week |
| |
| Report Available: |
3-5 days (may be extended if reflex testing required) |
| |
| Specimen Requirements: |
| Minimum Volume: |
2 mL serum |
| |
| Container: |
Gold top (serum separtor) tube |
| |
| Special Instructions and/or Comments: |
• DO NOT confuse with orders for Antinuclear Antibody Screen (ANA) or Antinuclear Antibody Profile, Comprehensive (ANAP) • No further reflex testing is performed if the initial ANA Screen is <1:80. |
| |
| Reference Range: |
| See individual test listings |
| |
| Clinical Utility: |
| Initial screen for evaluation of connective tissue disorders, with reflex to more specific autoantibody testing when screen results are positive. |
| |
Print |
| Antinuclear Antibody Profile, Comprehensive |
| |
| Includes: |
NOTE: DO NOT confuse with Antinuclear Antibody Screen. • Antinuclear Antibody Screen (ANA) • DNA Autoantibody, Double Stranded • SS-A Autoantibody • SS-B Autoantibody • Sm\RNP Autoantibody • Sm Autoantibody • Scl-70 Autoantibody • Reflexed when appropriate: • Titer and pattern of nuclear fluorescence on all positive screens |
| |
| CPT: |
86038, 86225, 86235 (5); Reflexed when appropriate: 86039, |
| |
| Alternate Name: |
• ANA Panel • ANAP • Antinuclear Antibody Profile |
| |
| Methodology: |
See individual test listings |
| |
| Testing Schedule: |
Routine, 2 times per week |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
2 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Reference Range: |
| See individual test listings |
| |
| Clinical Utility: |
| Comprehensive profile for initial evaluation of connective tissue disorders. |
| |
Print |
| Anti-Ovarian Antibody |
| |
| See Ovarian Autoantibody |
Print |
| Anti-Parietal Cell Antibody |
| |
| See Parietal Cell Autoantibody |
Print |
| Anti-Phosphatidylserine Antibody Profile, G/A/M |
| |
| See Phosphatidylserine Autoantibody Profile |
Print |
| Anti-Phospholipid Antibody Profile |
| |
| Includes: |
• Beta-2-Glycoprotein-1 Autoantibody Profile (G/A/M) • Cardiolipin Autoantibody Profile (G/A/M) • dRVVT Screen* • PTT (Lupus Sensitive)* • Thrombin Time • Interpretation • Reflexed when appropriate: ................dRVVT Confirm ................Hexagonal Phase Phospholipid Neutralization ................PTT Mixing Study ................Reptilase Time *When the Thrombin Time (TT) and Prothrombin Time (PT) are normal, at minimum, the PTT & dRVVT Screen are performed. |
| |
| CPT: |
86146 (x3) , 86147 (x3),85613, 85730, 85670 .....Reflexed when appropriate: 85597, 85732, 85635 |
| |
| Alternate Name: |
• APA; APL; Phospholipid Antibodies; • Phospholipid Autoantibodies |
| |
| Methodology: |
See individual test listings |
| |
| Testing Schedule: |
Routine, 1 time per week |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
4 mL prepared “platelet poor plasma”, split evenly into 4 plastic aliquot tubes, FROZEN immediately AND 1 mL serum |
| |
| Container: |
4 blue top (sodium citrate) tubes AND 1 gold top (serum separator) tube |
| |
| Collection: |
See special handling instructions for “Coagulation Studies”, listed under Specimen Collection, Preparation, and Handling Section |
| |
| Special Instructions and/or Comments: |
• Testing is contraindicated for patients on Heparin or Coumadin therapy. • Preparation and submission of “platelet poor plasma” is critical for accurate test performance and interpretation. See collection note above. Causes for rejection: • Extended transport time to laboratory • Clotted specimens • Hemolyzed specimens • Blue top sodium citrate tubes insufficiently filled • Aliquots not received frozen on dry ice • Frozen aliquots not clearly identified as “platelet poor plasma” |
| |
| Reference Range: |
| See individual test listings. |
| |
| Clinical Utility: |
| Phospholipid antibodies are associated with SLE, lupus-like disease, and the antiphospholipid syndrome (APS). Clinical problems are generally related to arterial and deep venous thromboses, recurrent spontaneous abortion, neurological and cardiological manifestations and thrombocytopenia. |
| |
Print |
| Anti-PM-1 Antibody |
| |
| See PM/Scl Autoantibody |
Print |
| Anti-Reticulin Antibody |
| |
| See Reticulin Autoantibody |
Print |
| Anti-Rh Globulin |
| |
| See Rh (D) Immune Globulin |
Print |
| Anti-RNP Antibody |
| |
| See ENA Autoantibody Profile |
Print |
| Anti-Ro |
| |
| See Sjögren’s Autoantibody Profile |
Print |
| Anti-Skeletal Muscle Antibody |
| |
| See Striated Muscle Autoantibody |
Print |
| Anti-Smooth Muscle Antibody |
| |
| See Smooth Muscle Autoantibody |
Print |
| Anti-Streptolysin O Antibody |
| |
| See Streptolysin O Antibody |
Print |
| Antithrombin III, Activity |
| |
| CPT: |
85300 |
| |
| Alternate Name: |
Antithrombin III Assay, Functional; AT-III, Heparin Cofactor Activity; Serine Protease Inhibitor |
| |
| Methodology: |
Chromogenic assay |
| |
| Testing Schedule: |
Routine, 1 time per week |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
2 mL prepared “platelet poor plasma”, split equally into 2 plastic aliquot tubes and FROZEN immediately |
| |
| Container: |
2 Blue top (sodium citrate) tubes |
| |
| Collection: |
See special handling instructions for “Coagulation Studies”, listed under Specimen Collection, Preparation, and Handling Section |
| |
| Special Instructions and/or Comments: |
• Testing is contraindicated for patients on Heparin or Coumadin therapy. • Preparation and submission of “platelet poor plasma” is critical for accurate test performance and interpretation. See collection note above. Causes for rejection: • Extended transport time to laboratory • Clotted specimens • Hemolyzed specimens • Blue top sodium citrate tubes insufficiently filled • Aliquots not received frozen on dry ice • Frozen aliquots not clearly identified as “platelet poor plasma” |
| |
| Reference Range: |
| 87% to 122% |
| |
| Clinical Utility: |
Useful for differentiating between Type I and Type II ATIII deficiency. ATIII deficiency, heterozygous state, Type I, has a relative risk of 5 for thrombosis; homozygous state Type I, is incompatible with life. Homozygous state Type II experience both arterial and venous thrombotic disease, often with severe complications. Elevated levels of ATIII are seen with an abolicsteriod use. Decreased levels of ATIII can be the cause of heparin resistance. |
| |
Print |
| Antithrombin III Assay, Functional |
| |
| See Antithrombin III, Activity |
Print |
| Anti-Thyroid Antibodies |
| |
| See Thyroid Autoantibody Profile |
Print |
| Anti-Thyroid Peroxidase Antibody |
| |
| See Thyroid Peroxidase Autoantibody |
| See Thyroid Autoantibody Profile |
Print |
| Antivirogram Phenotype |
| |
| See HIV-1 Phenotype |
Print |
| APL |
| |
| See Anti-Phospholipid Antibody Profile |
Print |
| APCA |
| |
| See Parietal Cell Autoantibody |
Print |
| APC-R |
| |
| See Activated Protein C Resistance |
Print |
| Apo A-1 |
| |
| See Apolipoprotein A-1 |
Print |
| Apolipoprotein A-1 |
| |
| CPT: |
82172 |
| |
| Alternate Name: |
Apo A-1, Apoprotein A1 |
| |
| Methodology: |
Rate Nephelometry |
| |
| Testing Schedule: |
Routine, 2 times per week |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Collection: |
Fasting patient preferred. |
| |
| Reference Range: |
• Male:...................115-190 mg/dL • Female:...............115-220 mg/dL |
| |
| Clinical Utility: |
| Low concentrations of apolipoprotein A-1, the major protein of high density lipoproteins (HDL), are more useful than HDL cholesterol, cholesterol or triglycerides in identifying individual patients with angiographic coronary-artery disease. Low concentrations of apolipoprotein A-1 are also more indicative of CAD when studied in survivors of myocardial infarction. |
| |
Print |
| Apolipoprotein B |
| |
| CPT: |
82172 |
| |
| Alternate Name: |
Apo B; Apoprotein B |
| |
| Methodology: |
Rate Nephelometry |
| |
| Testing Schedule: |
Routine, 2 times per week |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Collection: |
Fasting patient preferred. |
| |
| Reference Range: |
• Male:...........................70-160 mg/dL • Female:.......................60-150 mg/dL |
| |
| Clinical Utility: |
| LDL and its major protein, apolipoprotein B, play an essential role in lipid transport and metabolism. Apo B may regulate cholesterol synthesis through its interaction with specific cell membrane receptors and by inhibition of HMG Co A reductase. This enzyme has been identified as the rate controlling enzyme in cholesterol biosynthesis. Apo B may be important in the genesis of atherosclerosis and its quantitation useful in the evaluation of patients at risk for or having coronary atherosclerosis (CAD). High levels indicate increased risk for CAD. |
| |
Print |
| Apoprotein A1 |
| |
| See Apolipoprotein A-1 |
Print |
| Apoprotein B |
| |
| See Apolipoprotein B |
Print |
| APT Test |
| |
| CPT: |
83033 |
| |
| Alternate Name: |
Downey Test; Fetal • Hemoglobin Test in Newborns |
| |
| Methodology: |
Manual |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Container: |
Grossly bloody stool, blood stained diaper OR bloody gastric aspirate |
| |
| Reference Range: |
• Positive for fetal blood. • No maternal blood should be present. |
| |
| Clinical Utility: |
| Used to differentiate swalowed blood syndrome from gastrointestinal hemorrhage in the newborn. |
| |
Print |
| APTT |
| |
| See Partial Thromboplastin Time, Activated, Plasma |
Print |
| Arbovirus Antibody Profile RBOV |
| |
| Includes: |
• IgG and IgM Antibodies to each of the following: • California (LaCrosse) Encephalitis • Eastern Equine Encephalitis • St. Louis Encephalitis • Western Equine Encephalitis • West Nile Virus |
| |
| CPT: |
86651 (x2), 86652 (x2), 86653 (x2), 86654(x2), 86788. 86789 |
| |
| Methodology: |
Indirect Fluorescent Antibody (IFA) |
| |
| Testing Schedule: |
Routine, 2 times per week |
| |
| Report Available: |
5-7 days |
| |
| Special Instructions and/or Comments: |
| Refrigerate |
| |
| Reference Range: |
For each consitituent except West Nile Virus • IgG and IgM:.........................<1:16 titer • West Nile IgG and IgM:........<1:40 titer |
| |
| Clinical Utility: |
| Aid in the diagnosis of arboviral infection. IgG Antibody is usually detectable within 1 to 3 weeks of onset, peaking within 1 to 2 months and declining slowly thereafter. IgM class antibody is detectablewithin 1 to 3 weeks of onset, peaking and rapidly declining within 3 months. |
| |
Print |
| Arbovirus Antibody Profile, Cerebrospinal Fluid |
| |
| Includes: |
• IgG and IgM Antibodies to each of the following: • California (LaCrosse) Encephalitis • Eastern Equine Encephalitis • St. Louis Encephalitis • Western Equine Encephalitis • West Nile Virus |
| |
| CPT: |
86651 (x2), 86652 (x2), 86653 (x2), 86654(x2),86788, 86789 |
| |
| Alternate Name: |
Encehpalitis IgG and IgM Antibodies |
| |
| Methodology: |
Indirect Fluorescent Antibody (IFA) |
| |
| Testing Schedule: |
Routine, 2 times per week |
| |
| Report Available: |
3-5 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL frozen cerebrospinal fluid |
| |
| Container: |
Sterile conical tube |
| |
| Special Instructions and/or Comments: |
• Freeze specimen as soon as possible • Preferably within 4 hrs of receipt in the laboratory. |
| |
| Reference Range: |
| Negative........................ <1:2 for all constituents |
| |
| Clinical Utility: |
| Useful in the aid in the diagnosis of arboviral infection. IgG Antibody is usually detectable within 1 to 3 weeks of onset, peaking within 1 to 2 months and declining slowly thereafter. IgM class antibody is detectable within 1 to 3 weeks of onset, peaking and rapidly declining within 3 months. |
| |
Print |
| Arginine Vasopressin |
| |
| See Antidiuretic Hormone |
Print |
| Arsenic, Urine |
| |
| Includes: |
• Random Urine Arsenic • Arsenic/Creatinine Ratio |
| |
| CPT: |
82175 |
| |
| Methodology: |
Inductively coupled plasma Mass spectrometry (ICP-MS) |
| |
| Testing Schedule: |
Routine, daily |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
10 mL urine |
| |
| Container: |
Acid-washed plastic urine container |
| |
| Collection: |
Patient should avoid seafood consumption for 48 hours prior to collection |
| |
| Special Instructions and/or Comments: |
| Refrigerate |
| |
| Reference Range: |
• Arsenic/Creatinine ratio............<62.0 ug/g Creat • Arsenic, Random Urine............accompanies report |
| |
Print |
| Arsenic, 24-Hour Urine |
| |
| Includes: |
• Volume Measurement • Collection Period • Arsenic, Urine |
| |
| CPT: |
81050, 82175 |
| |
| Methodology: |
Inductively coupled plasma Mass spectrometry (ICP-MS) |
| |
| Testing Schedule: |
Routine, daily |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
25 mL aliquot of a well mixed 24-Hour urine collection |
| |
| Container: |
24-Hour plastic urine container, no preservative |
| |
| Collection: |
NOTE: Fish, shellfish and kelp should not be consumed for 48 hours prior to specimen collection. • Instruct the patient to void at the beginning of the collection period and discard the specimen. • Collect all urine, including the final specimen voided at the end of collection period. • Refrigerate during collection. • Container must be labeled with the patient’s name. |
| |
| Special Instructions and/or Comments: |
• Instruct patient not to void directly into container. • Transport to the laboratory promptly. |
| |
| Reference Range: |
• <120 µg/specimen • Toxic: > 5,000 µg/specimen |
| |
| Clinical Utility: |
| Detection of arsenic exposure |
| |
Print |
| Arsenic, Blood |
| |
| CPT: |
82175 |
| |
| Methodology: |
Inductively Coupled Plasma - Mass Spectrometry (ICP-MS) |
| |
| Testing Schedule: |
Routine, daily |
| |
| Report Available: |
3-5 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
5 mL whole blood |
| |
| Container: |
Royal Blue top trace metal tube, lavender label |
| |
| Special Instructions and/or Comments: |
• Store as whole blood in original tube. • DO NOT centrifuge, aliquot, or freeze. • Refrigerate only. |
| |
| Reference Range: |
| < 0.07 µg/mL |
| |
| Clinical Utility: |
| Useful in the detection of acutearsenic exposure. |
| |
Print |
| Arthropod Identification |
| |
| Includes: |
Arthropod identification including ticks, fleas, mites & lice |
| |
| CPT: |
87168 |
| |
| Alternate Name: |
Fleas; Lice; Ticks |
| |
| Methodology: |
Microscopic Identificiation |
| |
| Testing Schedule: |
Routine, Monday-Friday only |
| |
| Report Available: |
1-3 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
Intact Arthropod to be identified. |
| |
| Container: |
Submit in clean, dry container. |
| |
| Clinical Utility: |
| The identifcation of intact parasites may aid in the diagnosis and treatment of infested patients. |
| |
Print |
| ASA |
| |
| See Salicylate, Serum |
Print |
| ASCA |
| |
| See Saccharomyces cerevisiae Antibody Profile |
Print |
| Ascaris |
| |
| See Parasite Identification |
Print |
| Ascites Fluid Profile |
| |
| Includes: |
• Cell Count • Glucose • Lactate Dehydrogenase • Protein, Total |
| |
| CPT: |
89050,89051,82945,83615, 84157, 88107: |
| |
| Alternate Name: |
Fluid Analysis, Ascites Fluid |
| |
| Methodology: |
See individual test listings |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
2 mL ascites fluid in each tube |
| |
| Container: |
Red top tube, no serum separator AND lavender top (EDTA) tube |
| |
| Reference Range: |
| See individual test listings. |
| |
| Clinical Utility: |
| Used to evaluate fluid from the abdominal cavity and to differentiate exudates from transudates. |
| |
Print |
| Ascitic Fluid Culture |
| |
| See Culture, Fluid, Aerobic |
Print |
| Ascitic Fluid Cytology |
| |
| See Cytopathology, Fluid |
Print |
| Ashkenazi Jewish Profile |
| |
| Includes: |
• Canavan Disease Mutation Analysis • Cystic fibrosis Mutation Analysis • Familial Dysautonomia Mutation Analysis • Tay Sachs Enzyme Screen • Tay Sachs Mutation DNA |
| |
| CPT: |
83080, 83891 (X2), 83892 (X4) |
| |
| Alternate Name: |
• Ashkenazi Jewish Carrier Testing • Jewish Metabolic Profile • Jewish Profile |
| |
| Methodology: |
Fluorometric Enzymatic Assay and Polymerase Chain Reaction (PCR) |
| |
| Testing Schedule: |
Routine, Monday-Friday only |
| |
| Report Available: |
12-18 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
30 mL whole blood |
| |
| Container: |
3 Yellow top (ACD Solution A) tubes |
| |
| Special Instructions and/or Comments: |
• Collect Monday-Friday ONLY before 1400, no holidays. Specimens must arrive in the laboratory no later than 1600. • Store as whole blood in original tube at room temperature. • DO NOT centrifuge, aliquot, refrigerate or freeze. • Must provide patient’s ethnic background, family history and diagnosis on Requisition Form or Prescription. |
| |
| Reference Range: |
| See report. |
| |
| Clinical Utility: |
| Individuals identified as or descended from Ashkenazi (eastern European) Jews are a increased risk for many autosomal recessive genetic diseases. Carrier screening is useful to identify couples who, if both are carriers of one of these diseases, have a 1 in 4 chance of transmitting. |
| |
Print |
| ASL |
| |
| See Streptolysin O Antibody |
Print |
| ASMA |
| |
| See Smooth Muscle Autoantibody |
Print |
| ASO Titer |
| |
| See Streptolysin O Antibody |
Print |
| ASOT |
| |
| See Streptolysin O Antibody |
Print |
| Aspartate Aminotransferase, Serum |
| |
| CPT: |
84450 |
| |
| Alternate Name: |
• AST • GOT • Serum Glutamic Oxaloacetic Transaminase • SGOT |
| |
| Methodology: |
HNL Rate LPP Bichromatic Rate |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Reference Range: |
HNL: 7-40 units/L LPP: Female:.......................8-39 units/L Male:........................14-50 units/L |
| |
| Clinical Utility: |
| Useful in the evaluation of hepatic function and hepatic disorders. |
| |
Print |
| Aspergillus Ab Profile, |
| |
| Includes: |
• Aspergillus Precipitins • Aspergillus flavus IgE • Aspergillus fumigatus IgE • Aspergillus niger IgE • Aspergillus fumagatus IgG • Aspergillus niger IgG |
| |
| Methodology: |
See Individual Test Listings |
| |
| Report Available: |
3-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
4 mL serum |
| |
| Container: |
Two Gold top (serum separator) tube. |
| |
| Reference Range: |
| Accompanies Report |
| |
| Clinical Utility: |
| Positive results indicates exposure to Aspergillus, and the possibility of hypersensitivity pneumonitis. |
| |
Print |
| Aspergillus Antigen |
| |
| CPT: |
87305 |
| |
| Methodology: |
Immunoassay |
| |
| Testing Schedule: |
Routine, Mon-Fri ONLY |
| |
| Report Available: |
3-5 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top (serum separator) tube. |
| |
| Collection: |
• Centrifuge tube, transfer serum to plastic vial and freeze. • Serum can be stored : < 2 days refrigerated > 5 days frozen |
| |
| Reference Range: |
| Accompanies Report |
| |
| Clinical Utility: |
| Useful for the early diagnosis of invasive aspergillosis. This should be used and test results interpreted in conjunction with over conventional diagnostic procedures, such as microbiological culture, histologic examination of biopsy samples and other signs and symptoms for detection of Aspergillius infection. |
| |
Print |
| Aspirate Culture, Actinomycosis |
| |
| See Culture, Actinomyces, Anaerobic |
Print |
| Aspirin |
| |
| See Salicylate, Serum |
Print |
| Asthma Allergen Profile |
| |
| See Allergen Profile, Asthma |
Print |
| AT-III, Heparin Cofactor Activity |
| |
| See Antithrombin III, Activity |
Print |
| Ativan® |
| |
| See Lorazepam |
Print |
| Atypical Antibody |
| |
| See Type and Antibody Screen |
Print |
| Auramine Rhodamine Stain |
| |
| See Acid-Fast Stain |
Print |
| Aventyl® |
| |
| See Nortriptyline |
Print |
| Antigen B27 |
| |
| See HLA-B27 |
Print |
| Autoantibody,Cerebrospinal Fluid Human Chorionic Gonadotropin, Quantitative, Serum |
| |
| See Beta Human Chorionic Gonadotropin, Serum |
|